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The work presented in this thesis is concerned with the way in which a small 
peptide hormone, a-MSH, interacts with specific receptors on the surface of target 
cells. A systematic investigation into the structure-activity relationships of the 
interaction of the hormone with the MCI melanocortin receptor expressed by B16 
murine melanoma cells has been undertaken. Suitable analogues of a-MSH were 
synthesised by solid-phase techniques and were assayed for receptor binding, 
stimulation of tyrosinase and induction of melanin biosynthesis. Different series of 
peptides tested included a-MSH fragments, alanine substituted derivatives, cyclic 
peptides and analogues containing D-amino acids.
The amino acids responsible for the interaction with the receptor were identified as 
Met4, His6, Phe7, Arg8 and Trp9, and to a lesser extent, Pro12. The charged side- 
chains of the Glu5 and Lys11 did not seem to participate in either receptor binding 
or stimulation of biological activity.
Single amino acid replacement by alanine was recognised as the most valuable tool 
in investigating the role of individual residues. Therefore, the series of alanine- 
substituted a-MSH analogues was also tested for binding to a second melanocortin 
receptor, the MC3 receptor isolated from rat hypothalamus.
Binding to this brain receptor was determined by the same key residues (Met4, 
His6, Phe7, Arg8 and Trp9) as affinity and activity on the MCI receptor. An extra 
requirement exists for Tyr2. As all these residues can be found in all MSH/ACTH 
peptides, it is therefore suggested that this receptor might recognise the common 
core sequence of all MSH peptides, a -M S H ^.
Binding to both receptors was compared and a mechanism for the molecular 
interaction with the receptor is proposed.
CHAPTER 1
Introduction
The melanotropic peptides were among the first peptide hormones to be 
recognised and isolated, and have been extensively studied throughout this 
century. These studies, however, have almost exclusively been carried out in 
amphibia and reptiles, and their role in mammals has remained unclear until 
recently. A variety of new effects of MSH peptides has been discovered over the 
past fifteen years. The synthesis of potent and radiolabelled synthetic analogues 
made it possible to study the binding of the hormones to specific receptors and 
measure the biological response. The recent availability of the amino acid 
sequences of five subtypes of melanocortin receptors will allow insight into the 
molecular interaction of the hormone with the receptors. MSH peptides actively 
participate in skin pigmentation, and as receptors for melanotropic peptides are 
found in mammalian melanoma cells, they are of therapeutic and diagnostic interest 
in the treatment of the disease.
As malignant melanoma is resistant to most conventional therapies, it is mainly 
treated surgically but, because of its tendency to metastasise at an early stage, 
complete removal of the tumours is not always possible. It is therefore important 
to find a more efficient way of treating the disease as well as improving imaging 
techniques, both of which could be achieved potentially by a specific carrier that 
can target both drugs and imaging agents to melanoma cells. This could be a 
potential role for melanotropin analogues.
The rationale behind the concept of drug targeting is to achieve a desired 
pharmacological response at a selected site without undesired actions at non-target 
sites, or premature metabolism of the active drug (Gardner, 1985). To this aim, 
drug molecules have been linked to numerous classes of carriers, for example 
lectins, glycoproteins, enzymes, antibodies, poly- and oligo-peptides (see section
1.1.) and DNA (see Gregoriadis, 1979; Goldberg, 1983), to achieve a more site- 
specific delivery of the molecule.
1.1. Peptides hormones as carriers in drug targeting
Small peptide hormones have been considered an alternative to antibodies and Fab 
fragments in drug targeting; their uptake into cells is receptor-mediated, and 
therefore specific for a certain type of cell. Also, peptide hormones do not possess 
the same immunogenic potential as antibodies being naturally occurring molecules, 
and of low molecular weight. However, the interactions of the hormone with other 
cell types expressing the target receptor or a receptor for a structurally related 
hormone have to be considered (e.g. receptors for ACTH in the case of a-MSH). 
If the drug-hormone conjugate is to be administered systemically, it has to be 
ensured that the drug concentration at the target site is high enough, and that the 
conjugate is not broken down in the plasma to give the free hormone and the free 
drug. There are certain pharmacokinetic problems associated with the use of 
peptides as drugs or carrier molecules, such as their poor bioavailability after oral 
administration, their poor uptake across biological membranes, and their rapid 
clearance.
An ideal peptide-drug conjugate would be rapidly and specifically taken up by the 
target cell; this requires a high affinity of the conjugate for the receptor, and a high 
rate of endocytosis/intemalisation. Ideally, the receptor would be rapidly recycled 
and would participate in multiple rounds of delivery (Basu, 1990). Once
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internalised, the conjugate would have to be broken down into the carrier and the 
active drug; with internalised ligand-receptor complexes, the site of this process 
would be the lysosome, and it has to be ensured that the active drug molecule then 
reaches the target compartment of the cell without being degraded.
A number of peptide hormones including a-MSH and p-MSH (see section 1.3.4), 
have already been employed in drug targeting experiments; however, most of them 
have shown poor results when carried out in vivo (Chang, et al., 1977; Oeltmann 
and Heath, 1979; Cowley et al., 1980; Varga and Asato, 1977; Lejeune and 
Ghanem, 1993). One of the problems is that most of the receptors that have been 
well characterised (i.e. insulin-receptor, LDL receptors etc.) are present on a large 
number of different cell types, and selective delivery is therefore not possible.
1.2. Importance of understanding the structure-activity 
relationships
To make the best use of peptide carriers or targeting agents it is important to fully 
understand the way the molecule interacts with its receptor and the biological 
response it triggers. Knowledge of the organisation of the information within the 
molecule and, where possible, using this knowledge to optimise the molecule, are 
the key factors in the successful design and employment of peptide hormone drugs 
and carriers. The three-dimensional structures of a natural or synthetic small linear 
peptide are generally unpredictable, because they are too flexible to allow 
conformational studies by the conventional means of NMR and CD studies, 
likewise their biological properties are also unpredictable.
For example most of the biological activity of ACTH is retained by the 1-24 amino 
acid fragment; the remaining 15 amino acids appear to be dispensable (Schwyzer,
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1977). This has been observed with a number of other peptide hormones and 
growth factors as well. Also in ACTH, it was observed, that within the 1-24 
fragment, the first 10 amino acids appeared to be coding for the biological activity 
of the hormone, whereas the maximal binding affinity seemed to be determined by 
the 11-24 part of the molecule. This observation was the foundation of the so- 
called message-address concept (Schwyzer, 1977), which has since been 
successfully employed to design agonists and antagonists of naturally occurring 
peptides (Portoghese et al., 1990). The influence of individual amino acids and 
their side-chains is usually investigated by single amino acid replacements with 
natural or synthetic amino acids and their analogues. The physico-chemical 
properties of the substituted amino acid are of great importance, and only one 
parameter (i.e. hydrophobicity, steric bulk, electronegativity etc.) should be 
changed at the time to allow an estimate of which properties are required in each 
position. Attempts have been made to quantify these influences, but, although this 
is a good model in theory, it is seldom possible to achieve (Fauchere, 1986).
Insight into the active conformation of the peptide can be obtained using 
spectroscopic methods, and also by testing conformationally restricted analogues 
for activity in vitro. Conformationally restricted analogues include both cyclic or 
cross-linked derivatives, and those where amino acids have been replaced by their 
D-isomer. It is agreed that the perfect complementarity between receptor and 
ligand is only achieved when the peptide is bound to the protein, however, it has 
been postulated that a preferred, energetically sensible conformation exists which 
is close to the one recognised by the receptor. Of course it is also possible that a 
number of low energy conformations exist, and the molecule only acquires the 
active conformation in the process of binding to the receptor.
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1.3. Melanotropic Peptides
The melanotropic peptides are a group of structurally related pituitary peptide 
hormones that derive from the same precursor molecule, pro-opiomelanocortin 
(POMC). After excision of the signal peptide, POMC matures into P-lipotropin (P- 
LPH), ACTH and an N-terminal glycopeptide, which contains the y-MSH 
sequence (Mains et al., 1977; Crine et al., 1978; Chretien et al., 1979; Crine et al., 
1979; Nakanishi etal., 1979; Crine et al., 1980; Gianoulakis et al., 1980; Gossard 
et al., 1980; Mains and Eipper, 1980; Miller et al., 1980; Seidah et al., 1981). 
ACTH is further processed to a-MSH and corticotropin-like intermediate-lobe 
peptide (CLIP), equivalent to ACTH(lg.39). P-lipotropin is broken down into y- 
lipotropin and p-endorphin, and those peptides are then processed to p-MSH and 
Met-Enkephalin, respectively (Fig. 1.1.).
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Fig. 1.1. Schematic representation of the bovine ACTH/p-LPH precursor as 
described by Nakanishi et al., 1979.
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MSH peptides, and a-MSH in particular, have been studied extensively over the 
past 80 years, and a number of extensive reviews are available (Eberle, 1988; 
Hadley et al., 1988). Information contained in these volumes is therefore only 
mentioned briefly, and only when relevant for the discussion. Functions and 
biological properties of p-MSH and ACTH are not discussed in detail as these 
molecules are not part of this study.
1.3.1. a-MSH
Mammalian a-MSH (Ac-Ser1-Tyr2-Ser3-Met4-Glu5-His6-Phe7-Arg8-Trp9-Gly10- 
Lysn -Pro12-Val13-NH2) is a basic tridecapeptide with an isoelectric point of 10.5-
11.0. It also exists in its des-acetyl- or di-acetyl forms. Its amino acid sequence 
was first published in 1957 (Harris and Lemer). It is synthesised mainly in the pars 
intermedia of the pituitary gland, but there is evidence that some peripheral tissues 
are also able to synthesise the hormone. Biosynthesis and secretion of a-MSH in 
the pituitary are controlled by a variety of different inhibiting and excitatory 
factors. A number of hormones and neurotransmitters are involved in the control 
of a-MSH release, including dopamine, serotonin, GABA, somatostatin, nor­
adrenaline and vasopressin (see Eberle, 1988, Chapter 10).
1.3.1.1. Distribution
In most species, a-MSH is mainly formed in the pars intermedia of the pituitary 
gland, or in the pars distalis in species that lack the pars intermedia. Within the 
pars intermedia, a-MSH- and P-MSH immunoreactivity is found within the same 
cells, whereas there was a-MSH detected in the corticotrophic cells in the pars 
distalis. In MSH producing cells, the peptides are detected together with non- 
POMC peptides such as gastrin, 5-sleep-inducing peptide and calcitonin-like 
immunoreactivity.
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Rudman et al. studied the occurrence of MSH peptides in various regions of the 
rat, bovine and human brain (Rudman et al., 1973, 1974). The highest 
concentration of the peptides was found in the hypothalamus, the lowest in the 
midbrain and the hippocampus. Several areas did not show the presence of MSH 
peptides.
a-MSH-like immunoreactivity can be detected in a variety of peripheral 
mammalian tissues, such as skin (Thody et al., 1983), testes (Margionis et al., 
1983), placenta (Clark et al., 1978) and the gastrointestinal tract (Fox and Kraicer, 
1981). There is evidence that a-MSH in the skin and in the gastrointestinal tract 
might not be of hypophysial origin as the a-MSH content in hypophysectomized 
rats in these tissues does not differ from normal animals (Thody et a l, 1983; Fox 
and Kraicer, 1981). a-MSH can also be found in a number of malignant tumour 
cells (Morano and Estivariz, 1987; Hirata et a l, 1976) and elevated plasma levels 
of the hormone have been reported in some melanoma patients (Ghanem et al., 
1986).
1.3.1.2. Functions
Although the role of a-MSH has been more extensively studied in reptiles than in 
mammals, this chapter is mainly concerned with the way a-MSH interacts with 
pigment and melanoma cells. The mechanism of interaction with the MSH receptor 
is briefly described, and relevant functions in other tissues are mentioned. A good 
summary of the data up to 1988 is given by Eberle (1988), therefore it is not 
extensively reviewed in this chapter.
1.3.1.2.1. Mammalian melanocytes and melanoma cells
Mammalian melanocytes are derived from the neural crest, from where they 
migrate into the dermis as undifferentiated melanoblasts. Following invasion of the
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dermis, they differentiate into melanocytes (Prota, 1967). Molecular mechanisms 
of the formation of melanins as well as their exact chemical structure are only 
partly understood. Eumelanin and phaeomelanin seem to be under different genetic 
control, but part of their biosynthetic pathway is the same (Fig. 1.2.). Both 
originate from the same precursor, L-tyrosine, which in the first step is oxidised to 
L-DOPA and DOPAquinone. For the formation of phaeomelanin, this is then 
conjugated with glutathione or cysteine to cysteinyldopa, which is then oxidised to 
cysteinyldopaquinone, forms 1,4-benzothiazines and is processed in several steps 
to phaeomelanin. For eumelanin biosynthesis, the dopaquinone is processed to 
dopachrome, 5,6-dihydroxyindole and indole-5,6-quinone, which is able to form 
dimers called melanochrome. All these four molecules are involved in the 
formation of eumelanin (Prota, 1980). Tyrosinase (monophenol dihydroxy- 
phenylalanine:oxygen oxidoreductase; E.C. 1.14.18.1.) catalyses the first two steps 
of this pathway and is generally regarded as the key enzyme in melanogenesis. The 
expression of tyrosinase, however, is not variable in different skin types (Prota, 
1992); therefore another regulating factor must be involved in melanin 
biosynthesis. Recent results suggest that (6R) 5,6,7,8-tetrahydrobiopterin might be 
participating in regulating the tyrosine supply to melanocytes as it is a cofactor for 
phenylalanine hydroxylase, the enzyme that catalyses the conversion of L- 
phenylalanine to L-tyrosine (Schallreuter et al., 1994).
In cultured murine melanoma cells, internalisation of the receptor-ligand complex 
can be observed almost immediately after the binding to the receptor. It is believed 
that, once in the cell, the complex is degraded in the lysosome, as this procedure 
can be prevented by the acidotrophic agent NH4C1 (Adams, 1993). Internalisation 
might be followed by down-regulation of the a-MSH receptors on the cell surface 
(Eberle, 1993). A much slower internalisation rate can be found in human 
melanoma cells (Siegrist et a l , 1993). An increase in adenylate cyclase activity is 
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Fig. 1.2. Metabolic pathway from L-tyrosine to melanin. From: Eberle, 1988, 
p.231
receptor, reaching an early peak and then decreasing, before maximum binding is 
reached (Fuller et al., 1979; Fuller et al., 1987; deGraan et al., 1987). From there, 
two possibly equally important signalling pathways are stimulated:, the activation 
of protein kinases and the stimulation of protein phosphorylation. The latter leads 
to hydrolysis of phosphatidyl-inositol-4,5-diphosphate, which ultimately leads to 
diacetylglycerol production and stimulation of protein kinase C (Buffey et al., 
1992); membrane bound protein kinase C appears rapidly with a peak response 
after 20-60 min, and then decreases After 24h of exposure, levels of protein 
kinase C are back to residual activity. A phosphorylated 34kDa protein can be 
isolated from the culture medium after 5-20 min, whereas the time-course of the 
appearance of active tyrosinase is dependent on transcription.
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There has been some interest in the relationship between melanogenic response 
and metastastic potential of the cells. Lunec et al. (1992) report that both 
melanogenesis and metastatic activity of the cells are increased by a-MSH 
peptides, which is surprising as metastatic activity is usually associated with loss of 
differentiation. Also, it is likely that both responses are mediated by the same 
receptor as melanoma cells seem to possess only one population of a-MSH 
receptors. It has been observed that the melanogenic response and metastatic 
activity might depend on different signalling mechanisms following activation of 
the receptor. The melanogenesis of B16 melanoma cells seemed to depend on the 
cell density, but the metastatic potential did not (Buffey et al., 1992). Also, the 
Ca2+-channel blocking agent verapamil enhances the melanogenesis without 
affecting the metastatic activity of B16 murine melanoma cells (Parker and 
Sherbet, 1993). This is in agreement with the finding that Ca2+ plays an important 
role in the receptor activation and cell signalling of melanocortin receptors in 
melanoma cells.
Ca2+ is believed to be equally important for receptor binding and signal 
transduction (Gerst and Salomon, 1987a,b). This effect can also be observed with 
ACTH receptors from adrenocortical cells (Cheitlin et al., 1985) and might be a 
characteristic of this class of receptors. Recently, calmodulin-binding peptides have 
been shown to specifically inhibit the action of a-MSH on M2R melanoma cells 
(Eshel and Salomon, 1994).
In melanoma cells, a-MSH also affects the cell differentiation, proliferation and 
metastatic potential. It is not quite clear whether amelanotic melanoma cell lines 
form a better model regarding metastatic forms of melanoma. There have been 
reports of B16 murine melanoma cell subclones that lack the MSH receptor 
completely (Solca et al., 1993). Most of these studies were carried out using
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murine melanoma cells, but more recently, human melanoma cell lines have also 
been extensively studied.
a-MSH was reported to decrease the growth of Cloudman S91 melanoma cells 
whereas ACTH did not affect cell proliferation (Cobb and McGrath, 1974). 
However, in cells that are resistant to a-MSH, i.e. amelanotic lines, enhancement 
of the cell growth was observed (Halaban and Lemer, 1977). Similar observations 
were made when depleting normal S91 cells of tyrosine. With B 16 murine 
melanoma, the same effects could be found (Niles and Logue, 1979) and are 
believed to be concentration dependent (Siegrist and Eberle, 1986).
1.3.1.2.2. Role o f a-MSH in the central nervous system
The first report of MSH functions within the mammalian brain dates back to 1958, 
when Ferrari showed that intracistemal injection of MSH/ACTH peptides induced 
changes in the behaviour of dogs, rats, cats and rabbits (Ferrari, 1958). DeWied et 
al. showed that MSH/ACTH peptides improve avoidance learning in 
hypophysectomised rats (deWied et al., 1964, 1965, 1966). Also MSH peptides 
were found to have an influence on the grooming behaviour of rats. This effect 
was shown to be dependent on the nature of the peptide: of all naturally occurring 
ligands, a-MSH had the strongest effect, followed by p-MSH and ACTH(1.24), 
whereas y2-MSH, ACTH^o) and [Leu9]a-MSH were inactive. The synthetic, 
"superpotent" [Nle4,D-Phe7]a-MSH was even more active than a-MSH (Aloyo et 
a l, 1983).
a-MSH also shows some actions as a neurotransmitter, and it interferes with the 
cholinergic, (nor-)adrenergic, dopaminergic, serotoninergic and GABAergic 
systems (see Eberle, 1988).
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Intravenous injection of either a-MSH or Org 2766, a synthetic ACTH analogue 
([Met(02)4, D-Lys8, Phe9]ACTH(4 _9)), has been reported to reduce the local 
permeability of the blood-brain barrier (Goldman and Murphy, 1981). The 
analogue Org 2766 also appears to facilitate nerve recovery from lesions and 
cisplatin-induced neurotoxicity (deKoning et a l, 1988).
Both MSH and ACTH were found to exhibit antipyretic action in pyrogen-induced 
fever and, given in higher dose, ACTH^.^ and a-MSH also lowered the core 
temperature of afebrile rabbits (Glyn and Lipton, 1981; Murphy et al., 1983). 
Centrally administered a-MSH was 25,000 times more active than acetaminophen 
(paracetamol); a mechanism which might be mediated by a functional antagonism 
between interleukin-1 and a-MSH. The tripeptide Ac-a-M SH ^.^ was also able 
to exhibit antipyretic effects, but it is less active than the full-length peptide 
(Richards et al., 1984). D-amino acid replacement in positions 13 alone or 11 and 
13 increased the antipyretic and antiinflammatory actions of the tripeptide, but 
replacement of proline in position 12 by its D-isomer left the peptide inactive (Hiltz 
et al., 1991). In a study in rats, however, a-MSH and [Nle4,D-Phe7]a-MSH were 
shown to increase the core temperature rather than having a hypothermic effect 
(Raible and Knickerbocker, 1993).
a-MSH was shown to specifically inhibit the ability of interleukin-1 to participate 
in the proliferation of murine thymocytes and interleukin-1 induced synthesis of 
prostaglandin E in a dose-dependent way, whereas [Nle4,D-Phe7]a-MSH could 
not exhibit these effects (Cannon et al., 1986). Centrally administered a-MSH 
could also antagonise the actions of the pro-inflammatory agents interleukin-1(3, 
interleukin-8, leukotriene B4 and platelet-activating factor (Ceriani et a l, 1994). In 
this study, a -M S H ^.^  was also active in inhibiting interleukin-ip.
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Finally, a-MSH was found to modulate cardiac contractability, excitability and 
sensitivity to noradrenalin (Strand et al., 1986), an effect which might be 
controlled by the CNS. A recent study suggested that the effects of ACTH(1.24) and 
[Nle4,D-Phe7]a-MSH on blood-pressure and the incidence of grooming behaviour 
might be causally related (Versteeg et al., 1993).
The existence of these diverse functions of MSH in the brain indicate functionally 
distinct melanocortin receptors might exist. Two G protein-coupled melanocortin 
receptors found in the brain have recently been cloned and named MC3 and MC4 
(Gantz et al., 1993a,b; Roselli-Rehfiiss et al., 1993). There is further evidence of 
at least one more melanocortin receptor from the brain (Chhajlani et al., 1993). 
Heterogeneity of the brain melanocortin receptors was also suggested by Tatro 
and Entwistle (1994), who performed in situ binding studies on tissues from 
different parts of the brain. a-MSH, desacetyl-a-MSH, 0-MSH and ACTH were 
able to displace binding of [125I-Tyr2,Nle4,D-Phe7]a-MSH from the binding sites, 
but the biologically active derivatives Org 2766, A C T H ^  and a-MSH(11.13) could 
not inhibit the binding of the radiotracer.
1.3.1.3. Structure-activity relationships
Structure-activity relationships of a-MSH have been widely investigated, and are 
extensively reviewed in the literature. This section is meant to present a few main 
features of the structural interaction with pigment cells, but not a complete review 
of all the data available in the literature. Most of the studies concerning the 
structure-activity relationships of a-MSH have been carried out prior to 1988, and 
have been reviewed by Eberle (1988). More details on relevant information from 
previous studies are given in the appropriate discussion chapter (Chapter 4) and 
they are therefore not referred to individually here.
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1.3.1.3.1. Terminal amino acids
Des-acetylation is reported to decrease the potency of the peptide approximately 
10-fold in the frog skin assay, but not in other assay systems. Omission of the C- 
terminal amide does not alter the biological activity of the peptide. There has been 
some evidence that the C-terminal tripeptide might contain a "secondary message 
sequence" (Eberle and Schwyzer, 1975), but other studies showed that the 
tripeptide does not significantly increase the activity of some a-MSH fragments 
(Hruby et al., 1987). N-terminal amino acids 1-3 are thought to be unimportant for 
the peptide's action, and Hruby's group frequently employ a -M S H ^^  analogues 
in their studies.
1.3.1.3.2. Core sequence
Within the "core sequence", the importance of the central heptapeptide a-M SH^ 
10) was recognised early on, but no systematic approach has been taken to elucidate 
the importance of individual residues. The glycine in position 10, however, was 
later shown to be replaceable (Medzihradsky, 1976) and acting as a spacer 
between the core sequence of the hormone and the C-terminal tripeptide. Thus, in 
this thesis, the core sequence is being referred to as a -M S H ^ . A number of 
amino acid replacements within this core sequence have been carried out with 
varying results. Substitution of Arg8 led to significant loss of activity in all cases, 
whereas Met4, His6, Phe7 and Trp9 could be replaced by related amino acids and/or 
their isomers.
1.3.1.3.3. Cyclic peptides
Cyclic, conformationally restricted peptides are a valuable tool in studying the 
active conformation of a peptide. Several attempts have been made to cyclise a- 
MSH, and all the attempts made are discussed in detail in Chapter 4. Briefly, there 
are three main groups of cyclic peptides. The first derives from [Cys4,Cys10]a- 
MSH, a cyclic analogue that was first described in 1982 (Sawyer et al., 1982).
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This analogue exhibits slightly higher activity than a-MSH in the frog skin assay, 
and similar activities in all other assays. A number of fragments and analogues of
r   >
[Cys4,Cys10]a-MSH have also been tested. Two other groups of cyclic peptides 
have been formed by introducing a lactam bridge into the molecule, and they
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derive from the general structures [Nle4,D-Om5,Glu8]a-MSH(4 .11) (Sugg et al., 
1988) and [Nle4,Asp5,D-Phe7,Lys10]a-MSH(4.10) (Hadley et al., 1989),
respectively.
1.3.1.3.4. [Nle4,D-Phe7]  a-MSH
Heat-alkali treatment of pituitary extracts has long been observed to prolong their 
melanotropic activity on melanophores (Lee and Buettner-Janusch, 1963). Sawyer 
et al. proposed that this might be due to racemisation, and as Met4 and Phe7 are 
more prone to racemisation than the other residues, they synthesised [Nle4]a-MSH 
and [Nle4,D-Phe7]a-MSH for biological testing. If [Nle4]a-MSH, where the 
residue in position 4 is no longer prone to racemisation, is exposed to hot alkali, 
the prolonged effect could nevertheless be observed. Thus, it had to be mediated 
by racemisation of the Phe7 residue. [Nle4,D-Phe7]a-MSH proved to be more 
active than a-MSH, and showed prolonged effects in some of the assays (Sawyer 
et al., 1980). It also shows a higher binding affinity, which is suggested to be due 
to "irreversible" binding to receptor, and a higher stability towards degradation and 
oxidation. [Nle4,D-Phe7]a-MSH can easily be radioiodinated at the tyrosine in 
position 2 without destroying the biological activity of the molecule.
[D-Phe7]a-MSH has not been extensively studied, but seems to be almost 
equipotent to [Nle4,D-Phe7]a-MSH. It could therefore prove more suitable than 
[Nle4,D-Phe7]a-MSH for binding studies in human melanoma cells because of the 




Desacetyl-a-MSH (McCormack et al., 1982), a-MSH(1.g) (Eberle et al., 1984) and 
several modified C-terminal peptides have been shown to partially inhibit the action 
of a-MSH at concentrations where they do not exhibit activity themselves. At a 
sufficiently high concentration they do however exhibit agonist activity. This has 
also been reported for y-MSH (McCormack etal., 1982). Ac-Nle-Asp-Trp-D-Phe- 
Nle-Trp-Lys-NH2 has been described as a selective antagonist of a-MSH in the 
frog skin assay, but is inactive in the lizard skin assay (Al-Obeidi et a l, 1990). 
Cyclisation of this peptide between Asp and Lys restored its melanotropic activity. 
There are no antagonists described that inhibit a-MSH action in mammalian 
melanoma cells.
1.3.1.4. Use o f a-MSH in tumour imaging and drug targeting
Several attempts have been made to employ MSH peptides as carrier molecules in 
selective drug delivery. The earliest study was by Varga et al. (1977), who 
conjugated (3-MSH with daunomycin and achieved a three times higher toxicity 
compared to free daunomycin, while the conjugate was practically non-toxic to 
3T3 fibroblasts. Later investigations focused more on the a-MSH molecule, 
presumably because it is shorter - and therefore cheaper to synthesise- and also 
exhibits a higher affinity for the melanoma cell MSH receptor.
Melanoma selective cytotoxicity was observed with a diphtheria toxin-related a - 
MSH fusion protein (Murphy et a l, 1986). This protein was produced by genetic 
engineering in E. coli and was tested against human NEL-M1 melanoma cells in 
vitro. The fusion protein was not toxic for Chinese hamster ovary cells (CHO-K1) 
or green monkey kidney cells (CV-1) which do not express the a-MSH receptor. 
This fusion protein specifically interacts with the melanocortin receptors on the 
melanoma cells (Tatro et a l, 1992).
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A conjugate of the hormone with a monoclonal antibody to CD3, an invariant 
component of the T cell receptor complex, was used to target melanoma cells for 
destruction by human cytotoxic T lymphocytes, that otherwise bear no specificity 
for the tumours (Liu et a l, 1988).
An attempt to use melphalan conjugated to a-MSH in man has been made by 
Lejeune and Ghanem (1993), who tested the modified drug in two patients 
suffering from melanoma metastases. In one case, a complete remission for more 
than a year was achieved and although this is not a proof that drug targeting took 
place, this is a promising result, and the methods could be optimised in the future. 
Several a-MSH conjugates containing melphalan have also been tested in a human 
melanoma cell line, some of which were able to specifically bind to the MSH 
receptor. Although their cytotoxicity was less than that of the drug alone, it was 
cell specific, and the effect could be inhibited by excess a-MSH (Morandini et al., 
1994).
The possibility of employing a-MSH derivatives in the imaging of malignant 
melanoma has also been investigated (Bard et al., 1986; Bard et al., 1990). The 
most recent attempt was to employ a chelating derivative of a-MSH, tasMSH- 
DTPA (diethylenamine pentaacetic acid) which appeared to be equipotent to a- 
MSH in the Cloudman S91 tyrosinase assay and could be labelled with in In. 
Tumour associated radioactivity was significantly higher than activity in other 
tissues, and could be inhibited by excess a-MSH (Bard et al., 1990).
1.3.2. P-MSH
A greater variability is observed in the structure of P-MSH than in other MSH 
peptides. Some species might even express more than one form of the peptide (Lee 
et al., 1963; Ng et al., 1981). In mammals, the p-MSH sequence corresponds to
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the 41-58 amino acid region of the precursor P-LPH. Most mammalian p-MSHs 
contain the heptapeptide Met7-Glu8-His9-Phe10-Argn -Trp12-Gly13, the common 
melanocortin sequence. H-Asp1-Glu2-Gly3-Pro4-Tyr5-Arg6-Met7-Glu8-His9-Phe10- 
Argn -Trp12-Gly13-Ser14-Pro15-Pro16-Lys17-Asp18-OH is the most commonly found 
mammalian p-MSH sequence. In rats and mice, the POMC does not have a pair of 
basic residues between positions 59 and 60, so enzymatic cleavage between those 
residues might not take place, and it is not clear whether they are able to form p- 
MSH peptides. Systematic structure-activity studies with P-MSH peptides have 
not been undertaken; instead, the studies have been mainly restricted to the variety 
of naturally occurring analogues. In the Rana pipiens melanophore assay, monkey, 
pig and camel P-MSH are the most potent compounds exhibiting approximately 
25% of the activity of a-MSH (see Eberle, 1988, p.354). Its affinity to the MSH 
receptor in B16 murine melanoma was found to be 20% of that of a-MSH (Eberle, 
1988).
1.3.3. y-MSH
The analysis of the nucleotide sequence of the cloned cDNA for the bovine 
corticotropin-P-lipotropin precursor (=POMC) showed that a section of its N- 
terminal region contains the His-Phe-Arg-Trp tetrapeptide found in a-MSH, p- 
MSH and ACTH, and was therefore named y-MSH (Nakanishi et al., 1979). It 
was suggested that POMC may be processed by enzymatic cleavage between pairs 
of basic amino acids, Argr57-Lys'56 and Arg-^-Arg*42 or Lys*28-Arg-27 (Nakanishi et 
a l, 1979), thus giving the possible fragments Yj-MSH, y2-MSH and y3-MSH 
(Fig.7.3.).
The presence of these fragments in mammalian pituitary extracts have since been 
established (Bohlen et al., 1981; Tanaka et a l, 1980). y^MSH is preferentially 
found in the intermediate lobe of the pituitary, whereas y3-MSH is located in the
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anterior lobe (Wolter, 1984). The existence of pro-y-MSH containing a Lys- 
residue on the N-terminus has also been postulated (Bennett, 1986, Bennett et al., 
1986), and binding sites for Lys-y3-MSH were demonstrated in the rat adrenal 
cortex (Pedersen et al., 1983). This peptide, however, was unable to stimulate 
membrane-associated adenylate cyclase or guanylate cyclase activity.




Fig.1.3. Structure of y-MSH peptides as proposed from analysis of the gene 
encoding the precursor POMC
y3-MSH peptides were subsequently detected in neurones, nerve fibres and nerve 
endings in the rat duodenum (Wolter, 1984). Also, y-MSH like immunoreactive 
cell bodies were found in the nucleus tractus solitarii of the rat (Kawai et al., 
1984).
The exact biological function of y-MSH peptides is not yet known, although there 
are reports of them being involved in numerous clinical conditions. Elevated 
plasma levels of y-MSH have been associated with conditions as diverse as 
polycystic ovary syndrome, idiopathic hyperaldosteronism and cardiac arrest 
(Wortsman et al., 1984; Wortsman et al., 1985; Griffing et al., 1985). The
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presence in the nucleus tractus solitarii suggests that y-MSH peptides might be 
involved in the regulation of the cardiovascular system. Recent results have shown 
that y2-MSH especially is active in controlling blood pressure and heart rate 
(Versteeg et al., 1993; de Wildt et al., 1994). Interestingly, opposing 
cardiovascular effects can be seen depending on the site of administration, a 
depressor effect occurring after microinjection directly into the nucleus tractus 
solitarii and a pressor response following i.v. administration.
y3-MSH has been shown to stimulate secretion of corticosterone and aldosterone 
in frog interrenal glands in a dose-dependent manner (Leboulenger et al., 1986).
Within the pituitary, y-MSH peptides were unable to evoke the release of 
luteinising hormone, follicle stimulating hormone prolactin, growth hormone or 
thyrotropin (Ling et al., 1979). As a result it is unlikely that y-MSH peptides have 
a role as releasing factors for anterior pituitary hormones.
Yj-MSH, Ac-y,-MSH, y2-MSH and y3-MSH were tested in the Rana pipiens 
melanophore assay (Ling et al., 1979). All peptides were able to stimulate the 
melanocytes, but only at very high concentrations compared to a-MSH. The most 
active peptide in this assay was Ac-y^MSH, a peptide synthesised in analogy to 
the N-terminus of a-MSH. y3-MSH was the least active peptide in this study. In 
B16 melanoma cells, y-MSH peptides are reported to stimulate adenylate cyclase 
(MacNeill et al., 1981). In recent studies with Bomirski AbCl hamster melanoma 
cells and Cloudman S91 murine melanoma (cell lines normally responsive to P- 
MSH) y3-MSH alone was able to trigger the biological response in the hamster cell 
line, but not in Cloudman melanoma cells, and only at high concentrations (10pM). 
However, only two concentrations (lpM  and IOjiM) of the peptides were tested, 
and it is unlikely, but possible that the peptides either exhibit activities at higher 
concentrations or act as partial agonists, thus not reaching the maximal response
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triggered by P-MSH. All peptides were also tested for synergy with P-MSH. 
Whereas y2-MSH potentiated the effect of P-MSH when administered 
simultaneously, y3-MSH acted as a weak inhibitor of P-MSH induced tyrosinase 
activity (Slominski et al., 1992). It was therefore proposed that this biological 
action could be controlled by the C-terminal part of the peptide.
Receptor binding of y-MSH peptides has not been studied in melanocytes or 
melanoma cells.
1.3.4. ACTH
ACTH is not strictly speaking a melanotropic peptide, but it derives from the same 
precursor molecule, POMC, and because of its structural similarity to MSH (the 
first 13 amino acids of ACTH form a-MSH) it is able to evoke most of the actions 
of a-MSH with a lower potency. ACTH will interact with the a-MSH receptor, 
and shows approximately 10% of the affinity of a-MSH to the MCI receptor in 
melanoma cells (Eberle, 1988).
1.4. Melanocortin Receptors
Melanocortin receptors are a family of G protein-coupled receptors. They occur 
mainly in the central nervous system and in melanocytes. Molecular cloning of 
several receptors belonging to sub-families of melanocortin receptors has recently 
been reported (Mountjoy et al., 1992; Chhajlani and Wikberg, 1992; Gantz et a l, 
1993a,b; Roselli-Rehfuss et a l, 1993; Chhajlani et a l, 1993), and the sequences 
now available allow new insights into the interaction of melanotropic hormones 
with their receptors. Melanocortin receptors show features that are quite different 
from other neuropeptide receptors: they lack a number of amino acids usually 
found in G protein-coupled receptors and they also show a different
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transmembrane topology with the second extracellular loop being very 
hydrophobic. It has therefore been suggested that no significant extracellular 
domain exists in this part of the receptor (Cone and Mountjoy, 1993).
1.4.1. MCl-Receptors
The MCI receptor can be found in melanocytes and melanoma cells and is 
undoubtedly the most widely investigated of all melanocortin receptors. The amino 
acid sequence for the human and murine MCI has been independently reported by 
several groups (Mountjoy et a l, 1992; Chhajlani and Wikberg, 1992; Gantz et al., 
1993a). Whereas the human receptors described by Mountjoy et al. and Gantz et 
al. were identical, the one reported by Chhajlani and Wikberg differs by two amino 
acids. The murine and human MCI receptors are largely identical (Mountjoy et al., 
1992).
Chhajlani and Wikberg used competitive binding experiments in COS-7 cells 
transfected with the human MCI receptor to distinguish between ligand affinities 
to this receptor. Several melanotropic peptides were able to displace [125I- 
Tyr2,Nle4,D-Phe7]a-MSH in the following order: [Nle4,D-Phe7]a-MSH > a-MSH 
> ACTH > P-MSH > y-MSH > ACTH^,^. The non-melanotropic POMC peptide 
P-endorphin could not displace the radioactive ligand from the receptor.
Mountjoy et al. reported data from the cAMP assay for the receptor cloned from 
Cloudman S91 mouse melanoma: [Nle4,D-Phe7]a-MSH is the most potent ligand, 
followed by a-MSH and P-MSH with similar activities and ACTH with a slighter 
lower activity. y-MSH did not exhibit any biological activity (Mountjoy et a l,
1992).
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The MSH receptor from B16 murine melanoma cells has been characterised by 
photoaffinity labelling with a photoreactive mono-iodinated derivative of a-MSH, 
[125I-Tyr2,Nle4,D-Phe7, ATB-Lysn ]a-MSH (Ahmed et a l, 1992). After isolation 
of the ligand-receptor complex, SDS-PAGE and subsequent autoradiography, it 
appears as a doublet band of 43-46kDa. After deglycosylation, the receptor shows 
a single band of approximately 28kDa (Ahmed et a l, 1993), which suggests that 
the receptor exists in two very similar forms, which might vary in their 
glycosylation status. Several other groups came to similar results: Gerst et a l 
(1988) reported the presence of two receptor proteins of 43-46kDa on B16-M2R 
melanoma cells. Solca et a l (1989) found a hormone receptor complex of 45kDa 
on a panel of human and murine melanoma cells including the B16 and Cloudman 
S91 cell lines and later described the existence of three different receptor subtypes 
on various B16 mouse melanoma subclones (Solca et al., 1991).
Recently, a MCI-type receptor isolated from primary rat Schwann cells has been 
reported (Dyer et a l, 1993). This is the first receptor of this type that does not 
origin from melanocytes or melanoma cells. [125I-Tyr2,Nle4,D-Phe7,ATB-Lysn ]a- 
MSH photoaffinity labelled proteins were characterised by SDS-PAGE followed 
by autoradiography and show a doublet band of 42-45kDa similar to those 
observed in B16 murine melanoma cells (Ahmed et a l, 1992).
1.4.2. MC2-Receptor
In situ hybridisation shows that the MC2 receptor is localised in the adrenal cortex, 
mainly in the zona fasciculata, where glucocorticoids are produced and in the 
cortical half of the zona glomerulosa, the site of aldosterone production 
(Mountjoy et a l, 1992). It has been proven to be specific for ACTH by Northern 
blot analysis, and Cloudman S91 melanoma cells transfected with the gene for the 
MC2 expression respond to stimulation with ACTH peptides.
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1.4.3. MC3-Receptors
Molecular cloning of the rat MC3 receptor has been reported from the 
hypothalamus, and it also occurs in the limbic system (Roselli-Rehfuss et a l ,
1993). It contains 323 amino acids and is 43% identical to the MSH-R frpm 
melanocytes. In cells transfected with this receptor, [Nle^D-Phe^a-MSH 
stimulates cAMP synthesis most, followed by a-MSH, yj-MSH, y2-MSH and 
ACTH, which are equipotent. y3-MSH, desacetyl-a-MSH and ACTH^.^ are 
considerably less active and Org 2766 does not exhibit any activity (Roselli- 
Rehfuss et a l, 1993).
The human equivalent consists of 363 amino acids and can be found in the brain 
and in gut and placental tissues, but not in melanocytes or the adrenal gland (Gantz 
et al., 1993a). Adenylyl cyclase is activated equally well by a-MSH, P-MSH and 
y-MSH and ACTH(1.3 9), but to a lesser extent by ACTH(1_10) and ACTH 4^ _10).
Roselli-Rehfuss and co-workers suggest the possibility that this receptor might 
have a certain specificity for y-MSH peptides, although their physiological role is 
not yet understood. Gantz et a l , however, propose that the receptor recognises 
the nearly completely conserved core sequence of all melanocortin peptides, 
A C T H ^jq ).
Photoaffinity labelling of this receptor shows a single band at approximately 




The human MC4 receptor is expressed in the brain, but not in melanocytes, the 
adrenal cortex or the placenta (Gantz et al., 1993b). It responds equally to a- 
MSH, a-MSH and ACTH, but less well to y-MSH, ACTH^.^ and ACTH^^. It 
was suggested that it might require Tyr2 and Pro12 for stimulation of the biological 
activity. The physiological role of this receptor is not yet known.
1.4.5. Other melanocortin receptors
At least one other melanocortin receptor has been isolated (Chhajlani et al., 1993), 
and has also been assigned the name MC2 by its authors. Following the 
nomenclature practised by Cone et al. as well as Gantz et al., this would be a fifth 
melanocortin receptor. This receptor is expressed in the brain, but is not present in 
melanoma cells. This receptor shows a very high affinity to [Nle4,D-Phe7]a-MSH, 
followed by much lower binding of a-MSH and ACTH, which are equipotent, then 
by p-MSH and y-MSH. It is likely that in the future, several other melanocortin 
receptors will be detected in various tissues, and from various species.
1.5. Objectives
The work presented in this thesis was carried out as part of a research programme 
in selective drug delivery and targeting. The chosen model peptide, a-MSH acts 
on pigment cells, and was therefore selected as a putative carrier for the selective 
treatment of malignant melanoma. In spite of the clinical relevance of this model, 
this project was concerned with the fundamental understanding of receptor-ligand 
interaction and was aimed at evaluating the binding and activity properties of the 
a-MSH molecule. This has been attempted by systematically investigating the 
influence of individual amino acids and groups of residues on the peptide's
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interaction with melanocortin receptors, namely a MCI receptor from B16 murine 
melanoma cells and a MC3 receptor from rat hypothalamus. An attempt was made 
to investigate the bioactive conformation of the molecule. Most of this study was 
focused on the MCI receptor as it is relatively specific for a-MSH and its 
physiological functions are well established. The availability of a range of 
melanocortin receptor amino acid sequences and the existence of cell clones 
expressing large numbers of receptors isolated from the brain (e.g. the MC3 
receptor) has rendered it possible to investigate the interaction of the hormone 
with those receptors that provide a putative site for mediating CNS side-effects if 
a-MSH were to be used in drug targeting.
Terminal deletion fragments have been synthesised and tested for their binding 
affinity and biological activity in B16 murine melanoma cells. Several of these 
peptides have previously been investigated by other groups, yet many of these 
studies were carried out using reptilian bioassays and a systematic study has not 
been attempted in mammalian melanoma cells. An alanine scan was performed 
throughout the molecule to investigate the importance of residues within the 
peptide core. This technique has previously been employed to identify the amino 
acid side-chains involved in peptide hormone-receptor-interactions while leaving 
the stereochemistry of the backbone unchanged. Alanine substituted analogues of 
a-MSH were tested for receptor binding on the MCI and MC3 receptor and for 
biological activity on the MCI receptor. Derivatives of [Nle4,D-Phe7]a-MSH were 
tested for receptor binding and activity on the MCI receptor as [Nle4,D-Phe7]a- 
MSH is knowil to be a potent analogue of a-MSH. Replacement by D-amino acids 
might stabilise a reverse or (3-turn conformation of the peptide core backbone, 
which has previously been proposed. A cyclic a-MSH derivative and its linear 
analogue were studied in order to obtain information about the active 
conformation of the molecule.
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Reference peptides used in this study were a-MSH as the native ligand for the 
receptor on B16 murine melanoma cells, [Nle4,D-Phe7]a-MSH as a "superpotent", 
more stable analogue, employed as an internal standard in all assays, and Yj-MSH 
as the putative ligand for the MC3 receptor. y^MSH contains all the crucial amino 
acids from the a-MSH core sequence (a -M S H ^) and a possible specific 
physiological role for y-MSH peptides has been proposed on the MC3-R.
This study provides insight into the molecular mechanism of interaction between, 
a-MSH, and its receptors from peripheral tissues and the CNS. Residues 
participating in receptor-ligand interaction could be clearly identified, and the 







Water for preparation of cell culture media and solutions was freshly double glass 
distilled using a bi-distillation Fistreem still (Fisons Ltd.) fitted with a Fistreem 
predeionizer (Fisons Ltd.)
2.1.1.2. Balanced salt solutions
Phosphate buffered saline (PBS) without divalent cations was obtained from Oxoid 
Ltd in tablet form. One tablet was dissolved in 100ml of freshly double distilled 
water and autoclaved when required. Hank's Balanced Salt Solution and Dulbecco 
'B' were bought from Gibco as 10X liquid and diluted aseptically with freshly 
double distilled water. Solutions were stored at 4°C for up to four weeks.
2.1.1.3. Base and acid solutions
Solutions of 7.5% w/v sodium bicarbonate and 1M sodium hydroxide were 
prepared using double distilled water and were steam sterilised. 0.1 mM HC1 was 
prepared by diluting 1M HC1 (BDH Laboratory Reagents Ltd.) in double distilled 
water followed by filter sterilisation.
2.1.1.4. Ethylenediaminetetraacetic acid (EDTA)
A 0.02% w/v solution of the disodium salt (BDH Laboratory Reagents Ltd.) was 
prepared in PBS, sterilised and stored at -20°C for up to 4 months.
2.1.1.5. Trypan blue
The stain was obtained from BDH Laboratory Reagents Ltd. and dissolved at 
0.1% w/v in PBS.
2.1.1.6. Growth media and additives
All media and additives except some batches of foetal calf serum (FCS) were 
purchased from Gibco, Paisley. RPMI 1640 medium and Minimum Essential 
Medium (MEM) Eagle with Earle's salts were obtained as 10X concentrates 
without L-glutamine or sodium bicarbonate but containing phenol red. L-glutamine 
(200mM), a solution of penicillin (5000IU/ml) and streptomycin (5000mg/ml), 
non-essential amino acids and MEM vitamin solution were obtained as 100X 
concentrates and stored at the appropriate temperature.
FCS batches were tested for the support of cell growth before use. Batches used 
were 30A0212S (Gibco), 10855 (Flow) and 30F30315 (Gibco). It was added to 
the growth medium at a concentration of 10%.
Growth media were prepared aseptically according to the following recipe, stored 
at 4°C and used within a week of preparation. If required, the medium was 
adjusted to a final pH of 7.2-7.4 with 1M NaOH or 1M HC1.
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RPMI1640 MEM Eagle
10X RPMI 1640 50ml
10X MEM Eagle 50ml
L-glutamine 5ml 5ml
penicillin/streptomycin 5ml 5ml
MEM non-essential amino 5ml 5ml
acids
MEM vitamin solution 7.5ml
NaHC03 13.5ml 17.5ml




A laminar flow cabinet (MDH Ltd.) with vertical recirculation was used when 
aseptic techniques were required. Cells were maintained in a LEEC PF2 anhydric 
incubator (Laboratory and Engineering Company) with forced air circulation at 
37°C. The temperature control of the incubator was checked regularly. An 
inverted biological microscope, WILD M40 (Wild Heerbrugg Ltd) was used for 
examining cell growth and density. A standard double grid haemocytometer 
(Fisons Ltd.) was employed for determining cell numbers.
2.1.2.2. Disposable Items
Sterile tissue culture polystyrene flasks were regularly obtained from Falcon, 
Becton and Dickinson and Co.. 24- and 96-well plates were obtained from Nunc.
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Sterile screw capped tubes were obtained from Sterilin Ltd. Polypropylene 
ampoules (Coming) were used for storage of cells in liquid nitrogen.
2.1.2.3. Glassware
All glassware was rinsed in tap water immediately after use and then soaked in a 
2% solution of RBS 25 (Fisons Ltd.) for 30 min. Articles were subsequently rinsed 
in three changes of tap water and distilled water. Finally, items were left in double 
distilled water for lh, dried in an hot air oven (Gallenkamp), capped with 
aluminium foil and sterilised by dry heat at 160°C for lh (Gallenkamp sterilising 
oven).
2.1.3. Cell Culture Methods
2.1.3.1. Cell lines
A B16 murine melanoma cell line was donated by L. R. Kelland, Institute of 
Cancer Research, Sutton. Human 293 cells transfected with the genes for the 
expression of the MC3 receptor were supplied by R.D. Cone, Vollum Institute, 
Portland, Oregon.
2.1.3.2. Cell line maintenance and subculture
Cells from both cell lines were maintained in a LEEC anhydric incubator at 37°C 
under standard conditions of 95% air/5% C02 in a humidified atmosphere. 
Cultures were examined daily for microbial contamination. In order to maintain a 
pH of 7.2-7.4, the medium was routinely changed the day before the cells reached 
confluence. Subculture was undertaken with confluent cells by washing the cell 
monolayer twice with PBS and then incubating with a sufficient volume of 0.02% 
EDTA/PBS for lOmin. Detached cells were then diluted with culture medium to 
10ml, a sample taken and counted and flasks were inoculated with 2xl06 cells per 
175cm2.
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Cells used in the melanin biosynthesis assay were grown in MEM Eagle medium. 
The same routine was followed to maintain cultures for this assay.
2.1.3.3. Determination o f cell density
After detaching the cells from the flasks, a 0.4ml sample of the cell suspension was 
mixed with 0.1ml trypan blue solution. Viable cells exclude the dye, whereas non- 
viable cells are stained dark blue. The cells-dye mixture was then loaded onto a 
grid haemocytometer under a coverslip. A count of the four comers and the central 
square was made with an inverted microscope, then the number of cells was 
calculated using the following equation:
cells/ml= (total cells in 5 chambers x 104)/4
2.1.3.4. Cell storage and recovery
Cells were stored in 2ml ampoules in the vapour phase of a Union Carbide LR-40 
liquid nitrogen refrigerator at approximately -148°C. Cells were prepared for 
storage by detaching confluent cells from the flasks using the method described in 
section 2.1.3.2, suspending them in culture medium, centrifuging them for 10 
minutes at 1000 rpm and resuspending them in culture medium containing 10% 
dimethyl sulphoxide (Aldrich, spectrophotometric grade) as a cryoprotectant. 
Ampoules were then placed in a Union Carbide BF6 biological freezer unit plug 
and put in a Union Carbide LR-33 liquid nitrogen refrigerator to allow them to 
cool below -70°C at a rate of approximately 1°C min^.They were then transferred 
to the liquid nitrogen refrigerator for long term storage.
To recover cells from storage, the cryotubes were placed in a 37°C water bath and 
thawed. Cells were then suspended in 10ml of culture medium, centrifuged for 10 




All peptides except a-MSH, Ac-a-MSH^.^-NHj, Ac-a-MSH^.^-NHj and Ac- 
a-MSH(1.10)-NH2 were synthesised by Dr. G.W.J. Olivier, and their preparation is 
therefore not described in detail. y-MSH, a-MSH-COOH and [Cys4,Cys10]a- 
M S H ^^ were obtained commercially from Bachem, Basel, Switzerland. FAB-MS 
was carried out at Swansea University SERC Mass Spectrometry Service and 
MALDI-TOF MS by Kratos Analytical. Two Jeol FAB-MS spectra were provided 
by Dr. J. Thomas-Oates at the Mass Spectroscopy Centre, University of Utrecht.
2.2.1. Reagents
Amino acid derivatives, polydimethylacrylamide-Kieselguhr resin (Pepsyn K) and 
/?-[i£,S-a-l(9/f-fluoren-9-yl)methoxy-formamido-2,4-dimethoxybenzyl]phenoxy- 
acetic acid (AM-linker) were obtained from MilliGen, Watford. 
Hydroxybenzotriazole (HOBT), trifluoroacetic acid (TFA), diisopropyl- 
carbodiimide (DIC), 1,2-ethanedithiol (EDT), anisole and phenol were purchased 
from Aldrich, Gillingham, Dorset. Analytical and semi-preparative HPLC-columns 
were packed with Techsphere 10pm ODSWP(PTS 031 WP 300) as stationary 
phase (HPLC Technology, Macclesfield). Preparative HPLC was carried out using 
a C l8 protein-peptide column 25cm x 2.5cm i.d.. All other reagents were of 
analytical grade.
2.2.2. Synthesis of a-MSH, [Nle4,D-Phe7]a-MSH and a-MSH fragments
All peptides, except Ac-a-MSH(1.10)-NH2, for which a semiautomatic CRB- 
Pepsynthesiser H was used, were assembled on a MilliGen 9050 fully automatic 
synthesizer. They were prepared as their N-acetyl carboxyamide form by solid-
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phase synthesis using Fmoc-strategy (Atherton and Sheppard, 1989). Serine was 
used as the 3,4-dihydro-4-oxobenzotriazin-3-ylester, all other amino acids as 
pentafluorophenyl esters. Side-chain protecting groups were used as follows: 
arginine, methoxytrimethylbenzenesulphonyl (Mtr); glutamic acid, /-butoxy 
(OBut); histidine, /-butoxycarbonyl (Boc); lysine, (Boc); serine, /-butyl (But); 
tyrosine, (But). A four-fold molar excess of reagents was used at each coupling. 
Ac-a-MSf^i_!0)-NH2, Ac-a-MSH^i.j^-NHj, Ac-a-MSH^.^-NHj and a-MSH 
were deprotected and cleaved from the resin using 2% EDT, 2% anisole and 2% 
phenol in TFA overnight at room temperature. For Ac-a-MSH(2.13 )-NH2, Ac-a- 
MSH(3.13)-NH2, Ac-a-MSH(4_j3)-NH2and Ac-a-MSH(5.13)-NH2, 2.5% anisole and 
2.5% EDT in TFA were used. Deprotection and cleavage of [Nle4,D-Phe7]a-MSH 
employed 2% EDT, 2% anisole and 1% water in TFA. Peptides were purified by 
preparative HPLC using a gradient elution of 0.1% TFA in water and 0.1% TFA in 
90% acetonitrile/10% water at lOml/min. The eluent was monitored by UV 
spectrophotometry at 217 nm. Fractions were collected at 30s intervals and tested 
by analytical scale HPLC. Peptide identities were confirmed by FAB-MS or 
MALDI-TOF MS: a-MSH M+H calc. 1664.8, found 1664; [Nle4, D-Phe7]a-MSH 
M+H calc. 1646.8, found 1647; Ac-a-MSH^.^-NHj M+H calc. 1340.6, found 
1341; Ac-a-MSH^.nj-NHj M+H calc. 1468.7, found 1469; Ac-a-MSH^.j^-NHj 
M+H calc. 1565.7, found 1566; Ac-a-MSH^^-NHj M+H calc. 1577.8, found 
1578; Ac-a-MSH(3.13)-NH2 M+H calc. 1414.7, found 1415; Ac-a-MSH(4.13)-NH2 
M+H calc. 1327.7, found 1327; Ac-a-MSH(5.13)-NH2 M+H calc. 1196.6, found 
1197.
2.2.3. Synthesis of alanine-substituted analogues of a-MSH
Alanine analogues of a-MSH were synthesised in two parallel assemblies on the 
MilliGen 9050 automatic synthesizer. Fmoc amino acids were activated prior to
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reaction with 0-benzotriazol-l-yl-N,N,N1,N1-tetramethyluronium tetrafluoroborate 
(TBTU).
Side chain protecting groups were used as described above. Peptides were 
deprotected and cleaved from the resin using a mixture of 94% TFA, 2% anisole, 
2% EDT and 2% phenol and purified as before. Peptide identity was confirmed by 
FAB-MS or MALDI-TOF MS: [Ala^a-MSH M+H calc. 1648.8, found 1649; 
[Ala2]a-MSH M+H calc. 1572.8, found 1573; [Ala3]a-MSH M+H calc. 1648.8, 
found 1650; [Ala4]a-MSH M+H calc. 1604.8, found 1605; [Ala5]a-MSH M+H 
calc. 1606.8, found 1606.4; [Ala6]a-MSH M+H calc. 1598.8, found 1599; 
[Ala7]a-MSH M+H calc. 1588.8, found 1589; [Ala8]<x-MSH M+H calc. 1579.7, 
found 1579.5; [Ala9]a-MSH M+H calc. 1549.8, found 1551; [Ala10]a-MSH M+H 
calc. 1678.8, found 1679; [Alan ]a-MSH M+H calc. 1607.7, found 1608; 
[Ala12]a-MSH M+H calc. 1638.8, found 1639; [Ala13]a-MSH M+H calc. 1636.8, 
found 1637 (Sahme/a/., 1994).
2.2.4. Synthesis and cyclisation of [Cys4,Cys10]a-MSH
Synthesis was carried out as described above; the peptide was deprotected and 
cleaved from the resin using a mixture of 95% TFA, 2.5% EDT and 2.5% anisole. 
For the cyclisation, lOOmg of the crude peptide was dissolved in 3g of glacial 
acetic acid in a 500ml round bottom flask, the mixture was then degassed using 
N2. Approximately 250ml of degassed water was then added and the solution was 
titrated to pH 7.5 with NH4OH in a nitrogen atmosphere. The flask was filled to 
the neck with degassed water and the mixture was then exposed to air to allow the 
oxygen to dissolve slowly and oxidise the peptide until the cyclisation was 
complete. To test for cyclisation, the solution was co-chromatographed with the 
pure linear peptide as there are only marginal changes in retention time between 
the linear and cyclised form of the peptide. To separate the cyclised compound 
from the buffer, the solution was adjusted to contain 3.5% acetonitrile and passed
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through a C18 reverse phase Bond Elut column packed with Spherisorb ODS 
(Analytichem International). The column was washed with 3.5% acetonitrile to 
remove the salt. The peptide adsorbed to the column was then washed off with an 
acetonitrile-water mixture, lyophilised and purified by HPLC The washings were 
tested for absence of peptide by HPLC and further extractions using the Bond Elut 
column were performed until no trace of peptide was found in the buffer solution. 
Identity of the cyclised peptide was confirmed by FAB-MS: [Cys4,Cys10]a-MSH 
M+H calc. 1681.74, found 1682.
2.2.5. Synthesis of [Nle4,Asp5,D-Phe7, Lys10, Arg11]a-MSH
Synthesis was performed and purification was carried out as described in section
2.2.2. using pentafluorophenyl esters of the amino acids. Peptide identity was 
confirmed by FAB-MS: M+H calc. 1731.91, found 1733.
2.2.6. Synthesis of [Nle4,D-Phe7,D-Trp9]a-MSH
Synthesis and purification were carried out as described, using TBTU activation. 
Identity of the peptide was confirmed by FAB-MS: M+H calc 1646.8, found
1646.5.
2.2.7. Synthesis and cyclisation of [Nle4,Asp5,D-Phe7,Lys10] a-MSH
The peptide was assembled using TBTU activation as described above but using 
Fmoc-Asp(OAll)-OH for position 5 and Fmoc-Lys(Aloc)-OH for position 10. On 
the Pepsynthesizer n , protecting groups in positions 5 and 10 were then removed 
by recirculating for 2h with palladium-tetrakis-triphenyl phosphene in a mixture of 
5% glacial acetic acid and 2.5% TV-methyl morpholine in chloroform under 
exclusion of air. The resin was the washed with 0.5% diethyl-dithiocarbamate and
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0.5% DIPEA in DMF to remove the palladium complex, then with DMF. 
Cyclisation was started by activation with TBTU and ended when no free amino 
groups could be found. This method was first described by Kates et al. (1993). 
Deprotection and cleavage from the resin was carried out by reacting with 5% 
thioanisole, 3% EDT and 2% anisole in TFA for 16h at room temperature. The 
peptide was then purified by HPLC as described. FAB-MS revealed that this 
peptide was not cyclised, but was likely to still contain the Aloc-protection group 
on the Lys10. M+H calc. 1685.88, found 1783.9.
2.3. Radioiodination of [Nle4,D-Phe7]a-MSH
[Nle4,D-Phe7]a-MSH has been iodinated following a methodology described by 
Eberle (1988).
2.3.1. Solutions
The following solutions were prepared either immediately before use or stored at 
4°C where appropriate:
1) 0.25M NajHPC^ (FSA Laboratory supplies)
2) 0.25M NaHjPO,*
3) 1%TFA (Aldrich, analytical grade)
4) 50, 60 and 80% methanol containing 1% TFA
5) 0.25M phosphate buffer pH 7.4
6) 0.25% BSA in 0.05M phosphate buffer pH 7.4
7) 1% Polypep (Sigma) in 0.05M phophate buffer pH 7.4
8) 0.1% chloramine T (BDH Chemicals Ltd.) dissolved in water immediately prior 
to use
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2.3.2. Preconditioning of the Bond-Elut column
A C18 reverse phase 'Bond Elut' column packed with Spherisorb ODS was 
preconditioned by washing it in the following way:
3xlml 1% TFA 
3xlml 80% MeOH/l%TFA 
lxlml Polypep solution 
3xlml 80%MeOH/1 %TFA 
3xlml 1% TFA
2.3.3. Iodination
1.5pl of [Nle4,D-Phe7]a-MSH stock solution was diluted in 20pl of phosphate 
buffer. lOpl of Na125I solution and lOpil of chloramine-T solution were then added 
and allowed to react for 30s before addition of 0.6ml BSA solution. The reaction 
mixture was then applied to the preconditioned Bond-Elut column to remove free 
Na125I. The column was washed twice with phosphate buffer, four times with 50% 
methanol/1% TFA and twice with 60% methanol/1% TFA. The methanolic washes 
were then injected onto an analytical grade HPLC for further purification.
2.3.4. Purification
The methanolic fractions containing the iodinated peptides were purified by 
analytical scale HPLC using an exponential gradient of 0.1% TFA in water and 
0.1% TFA in 70% ACN/30% water. Fractions were collected at lmin intervals 
from 25 to 40 minutes after injection. The moniodinated peptide eluted before the 
di-iodinated derivative, but after the free [Nle4,D-Phe7]a-MSH (Fig. 2.1.). The
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radioactivity of the fractions was then counted, and those with radioactivity 
associated with the peak of the monoiodinated peptide pooled and their activity 
counted.
The radiolabelled peptide could be stored at -20°C for up to 20 days.
2.3.5. Calculation of radiotracer concentration
The concentration of radiotracer was calculated from the measured radioactivity 
by the following method:
Assuming a 1:1 ratio of 125I to [Nle4,D-Phe7]a-MSH (mono-iodinated [Nle4,D- 
Phe7]a-MSH by definition):
lmatom 125I = 103 moles [125I-Tyr2,Nle4,D-Phe7]a-MSH
and with a specific activity of 80.5x1012Bq/matom for carrier-free Na125I, 
lmole [125I-Tyr2,Nle4,D-Phe7]a-MSH would have an activity of 80.5xl012xl03Bq
As lBq=l decay per second=60 decays per minute and the effiency of the gamma- 
counter=70%:
70lmole [125I-Tyr2,Nle4,D-Phe7]a-MSH would register 80.5 x 1012x 103 x 60 x 
= 3.38 xlO18 cpm on the LKB 1277 Gammamaster.
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Fig. 2.1. Elution profile of mono- and di-iodinated a-MSH from analytical scale 
HPLC as described in section 2.3.4. Mono-iodinated a-MSH (1) elutes at 35min, 
di-iodinated (2) a-MSH at 38min
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2.4. Binding Assays
Binding assays were carried out following a method adapted from Siegrist et al. 
(1988) as described by Erskine-Grout (1993).
2.4.1. Binding medium
The binding medium consisted of RPMI 1640 medium without any additives, 
25mM N-(2-hydroxyethyl)piperazme-V-2-ethane sulphonic acid (HEPES) and 
0.2% BSA. HEPES and BSA were prepared as 10X concentrates in serum-free 
RPMI 1640, stored at -20°C and diluted immediately prior to the experiments.
2.4.2. Binding isotherm of [125I-Tyr2,NIe4,D-Phe7]a-MSH
Cells were detached from the flasks, counted and seeded at a density of 5x105 cells 
per well into 24-well plates. They were then incubated under standard conditions 
for 15h before being washed twice with ice-cold RPMI 1640 without additives and 
allowed to cool to 0-4°C while the binding buffer was being prepared. Various 
concentrations of [125I-Tyr2,Nle4,D-Phe7]a-MSH were added to the medium. Non­
specific binding was determined using a 1000-fold excess of non-labelled [Nle4,D- 
Phe7]a-MSH. 0.5ml of binding medium containing the radiotracer was added to 
the wells and the cells were incubated for 8h at 0-4°C. After the incubation, excess 
radiolabelled peptide was washed off with RPMI 1640, the cells lysed with 1M 
NaOH and the radioactivity counted on a LKB 1277 gammamaster gamma- 
counter. Estimates for receptor number and association constant were obtained 
using a non-linear least square regression suitable for ligand binding analysis (see
2.4.2.1.) A Scatchard plot was carried out to prove the homogeneity of the 
receptor population (Scatchard, 1949).
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2.4.2.1. Scatchard plot
Assuming equilibrium is reached between free and occupied receptors, the Law of 




with: [H] = concentration of free hormone
[R] = concentration of free receptor 
[HR] = concentration of hormone-receptor complex
if n = total number of receptors,
[R] = n- [HR]
and
K. ,  I™ !




where [HR]/[H] is the y-axis, [HR] the x-axis, the slope = -Ka and the x-intercept 
= n (Scatchard, 1949).
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2.4.3. Competition binding
Competition binding was studied using the assay protocol for the isotherm 
described in section 2.4.2., but with the binding buffer containing a fixed 
concentration of [125I-Tyr2,Nle4,D-Phe7]a-MSH, nominally O.lnM and serial 
dilutions of the test peptide, usually in the range of lO^to 1012 M.
2.4.3.1. Analysis o f binding data
MINSQ non-linear least square regression analysis was used to calculate 
dissociation constants from the competition binding data employing the following 
equation:
with cpm(test) = cpm for sample point
cpnimax = maximum bound (no competitor) 
cpnimin = minimum bound (excess competitor)
[A] = conc. of tracer
[B] = conc. of competitor
Km  and Kjg = dissociation constant of tracer and competitor, respectively
2.4.4. Binding to human 293 cells transfected with the gene encoding the 
MC3 receptor
Preliminary binding studies with the cells transfected with the gene that encodes 
the rat hypothalamus receptor were carried out at 37°C and 0-4°C. Time-course 
experiments at 0-4°C showed that equilibrium binding was reached after 24h (see 
Fig. 5.2.). A monolayer could not be maintained in 24-well plates at 0-4°C for
cpm(test) = Cpnimax - Cpnimin X [A]
[A]+K<!a x
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such a long period of time, so the experiments were carried out in 96-well filtration 
plates (nitro-cellulose filters, Millipore). The plates are made of a solvent resistant 
plastic with polyvinylidene difluoride sonically welded to the bottom of each plate 
which is removed after the incubation before counting the cell-associated 
radioactivity. These filter plates allow the washing of the cells to be carried out 
using a vacuum-manifold and detached cells are not lost during the washing 
procedure. The plates were inoculated with 105 cells per well and incubated for 4h 
at 37°C. After washing the cells three times with cold serum-free RPMI 1640 or 
PBS using the vacuum-manifold, 0.1ml of the binding buffer was added and a 24h 
incubation at 0-4°C followed. After the incubation, the cells were washed three 
times and the filters with the cells transferred to LP4 tubes using the Multiscreen 
Assay System (Millipore) after removing the polyvinylidene difluoride film from 
the plates. Control experiments with B16 cells were carried out to ensure that the 
multiscreen assay conditions did not affect the results.
2.5. Tyrosinase Activity Assays
The tyrosinase assay was based on a method described by Pomerantz (1966).
2.5.1. Assay medium
The binding medium consisted of RPMI 1640 containing 0.2pCi/ml of [3’,5'-3H]- 
L-tyrosine (Amersham). The radiolabelled amino acid was stored at 2-5°C and 
was added to the medium on the day of the experiment.
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2.5.2.3H20  standard curve
The standard curve was established using 3H20  internal standards from Pharmacia 
(Internal standard kit for liquid scintillation counting 3H in organic solvents, 
0.0909fiCi=3.36kBq) on a LKB Wallac 1215 Rackbeta liquid scintillation counter 
(Erskine-Grout, 1993)
2.5.3. Assay procedure
The cells were seeded in 24-well plates at a density of 3x104 cells/well and 
incubated under standard conditions for 15h. The medium was then replaced with 
assay medium containing serial dilutions of the test peptides and the plates were 
incubated at 37°C in 5%C02 for 48h. 0.9ml of the medium was then pipetted off 
into Eppendorf tubes and 0.2ml of a suspension of 10% dried charcoal in PBS was 
added. The mixture was agitated for 30min at 4°C and then centrifuged for 15min 
at 3500g (Erskine-Grout, 1993). 0.9 ml of the mixture was then added to 8ml of 
liquid scintillation fluid (Optiphase Safe, Pharmacia) and the radioactivity was 
counted using parameters matching the standard curve. To account for non- 
enzymatically generated ^ O ,  wells were incubated without cells in the assay 
medium under assay conditions and values were subtracted from the counts. EC50 
values were estimated using linear regression for the linear part of the dose- 
response curve.
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2.5.3.1. Calculation o f EC50 values
INSTAT linear regression analysis was performed on the linear part of the curve 
which can be described by the following equation:
dpm = M log[A] + c or log[A] = -
M
where dpm = 3H20  formation, measured as dpm 
log[A] = log concentration of agonist 
M = slope of the line 
c = y-axis intercept
As the EC50 is the point of the curve where 50% of maximum stimulation is 
reached,




The melanin biosynthesis assay was carried out following a procedure first 
described by Siegrist and Eberle (1986). For this assay, it was necessary to grow 
the cells in MEM Eagle with Earle's salts as melanin is not as readily soluble in 
RPMI 1640. Cells were plated in 96-well plates at a density of 2.5xl03 cells per 
well. After a 15h incubation under standard conditions, serial dilutions of the 
peptide were added in MEM medium containing 0.3mM L-tyrosine (Sigma) to 
serve as a substrate for melanin biosynthesis. After a 72h incubation at 37°C,
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melanin biosynthesis was measured spectrophotometrically on a Microplate reader 
(ICN/Flow) using 340nm and 405nm filters. A standard curve obtained with 
synthetic melanin (Sigma) was linear under the conditions of the experiment (Fig.
2.2.). Although the absorbance observed at 340nm was higher than at 405nm, the 
405nm filter was used routinely because the medium shows a relatively high 
absorbance at 340nm itself and readings at this wavelength repeatedly deviated 
from the linear range of the spectrophotometer (A>1.0).
2.6.1.1. Calculation o f EC50 values
The calculation of EC50 values was performed as described in section 2.5.3. but 
using absorbance values instead of dpm.
2.7. Statistical data analysis
Significant differences were determined from the data with a one way analysis of 
variance following Fisher's multiple comparison procedure at the 99% confidence 
interval unless otherwise stated. The analysis was carried out using MINITAB 9.1. 
The coefficient of variance associated with the four replicates wells for each 
concentration point in any of the assays was less than 10%. Results of the 
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Binding affinity and Biological Activity of a-MSH 
Derivatives in B16 Mouse Melanoma
This section describes the results obtained with the MCI receptor from B16 
murine melanoma cells in culture. Several groups of MSH peptides have been 
tested for receptor binding (see section 2.4.) and tyrosinase stimulating activity, 
some of them also for stimulation of melanin biosynthesis (see sections 2.5. and
2.6.). The results are discussed separately for the individual groups of peptides.
3.1. Binding isotherm of [125I-Tyr2,NIe4,D-Phe7] a-MSH
The dissociation constant (Kj) for [125I-Tyr2, Nle4, D-Phe7] a-MSH was obtained 
from five replicate binding isotherms and was estimated by MINSQ non-linear least 
squares regression to be 0.48±0.08nM. A representative isotherm is shown in Fig.
3.1.. Scatchard analysis of the binding isotherms, as described in section 2.4.2.1., 
showed that there was only one population of receptors present (Fig. 3.2.). The 
number of receptors per cell varied from 5,000 to 25,000.
3.2. Binding affinity and biological activity of a-MSH fragments
a-MSH fragments were tested to investigate the influence of the terminal ends 
(amino acids 1-4 and 10-13) of the peptide. The fragments described in this section 
are Ac-a-MSH(2.13)-NH2 Ac-a-MSH^^-NHj Ac-a-MSH(4.13 )-NH2 and Ac-a- 
MSH(5.13)-NH2 as well as Ac-a-MSH(1.10)-NH2, Ac-a-MSH^.^-NF^ and Ac-a- 
M S H ^ -N B ,.
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Fig. 3.1. Binding isotherm [125I-Tyr2,Nle4,D-Phe7]a-MSH to B16 murine 
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Fig. 3.2. Scatchard plot of a binding isotherm of [125I-Tyr2,Nle4,D-Phe7]a-MSH to 
B16 murine melanoma cells at 0-4°C, curved line shows 95% confidence interval.
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S. 2.1. Receptor binding
Dissociation constants (Table 3.1.) were estimated from the radioactivity 
associated with the cells as described in section 2.4.3.1.. The means and standard 
deviations of three or more experiments were determined for each peptide. Values 
relative to a-MSH are given in Table 3.2.. Representative examples of competitive 
binding isotherms are shown in Fig. 3.3.. Loss of the N-terminal serine did not 
affect the affinity of the peptide, but removal of the serine-tyrosine dipeptide in 
positions 1 and 2 led to a peptide with 11 % of the affinity of a-MSH, thus being 
significantly different from both a-MSH and Ac-a-MSH(2.13)-NH2. Removal of the 
three N-terminal amino acids (Ac-a-MSH^^-NH^ gave a peptide whose binding 
was not significantly different to a-MSH, Ac-a-MSH(2 .13 )-NH2 or Ac-a-MSH^. 
13)-NH2. Removal of the four amino acids up to and including Met4 reduced 
relative binding to 0.0016, and Ac-a-MSH(5.13)-NH2 had a significantly different 
binding affinity compared to a-MSH itself and the other N-terminal deletion 
fragments (Fig. 3.6.).
Omission of the C-terminal amino acid valine did not significantly affect the 
dissociation constant, but additional loss of Pro12 gave a peptide whose binding 
was significantly lower than that of a-MSH itself (relative binding 0.05). Ac-a- 
MSH(1.10)-NH2 showed a significantly lower binding than the natural ligand 
(relative binding 0.0087), Ac-a-MSH(1.12)-NH2 and Ac-a-MSH^.^-NHj (p<0.05). 
(Fig .3.7.)
3.2.2. Tyrosinase assay
EC50 values and standard deviations (Table 3.7.) were obtained from the data as 
described in section 2.5.3.1.. Each EC50 value is the mean of three or more 
replicate experiments. A representative example of the reproducibility is shown in 
Fig. 3.4..
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Loss of the three N-terminal residues (Ac-a-MSH(2_13 )-NH2, Ac-a-MSH(3 .13)-NH2 
and Ac-a-MSH(4 .13 )-NH2) did not significantly affect the biological activity of the 
peptide as measured by this assay. There was no significant difference in activity 
between any members of this group but removal of Met4 in Ac-a-MSH(5.13)-NH2 
produced a peptide which had significantly different tyrosinase activity to a-MSH 
itself (relative activity 0.001) and the other N-terminal deletion fragments (Fig.
3.6.).
The activity of Ac-a-MSH^.^-NHj was not significantly different to the native 
hormone but the activities of Ac-MSH(1.11)-NH2 and Ac-MSH(1.10)-NH2 were 
significantly lower, having relative potencies of 0.05 and 0.013 respectively. The 
activity of Ac-a-MSH(1.11)-NH2 was not significantly different to Ac-a-MSH^.^- 
NHjin contrast to the activity of Ac-a-MSH^.j^-NHj (p<0.05). The tyrosinase 
activities of Ac-a-MSH(1.11)-NH2 and Ac-a-MSH^.j^-NHj were not significantly 
different (Fig. 3.7.).
3.2.3. Melanin assay
In replicate experiments, the cell number per well increased to 25,000 cells per 
well during the 72h period. An example of the dose-response curve is given in Fig.
3.5..
Data from this assay were analysed as described in section 2.6.1.1. (Table 3.1., 
Fig.3.6., Fig. 3.7.). Values relative to a-MSH are given in Table 3.2.. Results from 
the melanin assay were generally in good agreement with those from the tyrosinase 
assay with respect to the pattern of relative potencies with one exception in the C- 
terminal deletion sequences: Ac-a-MSH^.^-NF^ showed significantly different 
activity to a-MSH itself (relative potency 0.03) and Ac-MSH^.^-NHj in the 
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Fig. 3.3. Competition binding of C-terminal deletion fragments of a-MSH to B16 
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Fig. 3.5. Stimulation of melanin biosynthesis by [Nle4,D-Phe7]a-MSH (NLDP) as 
a function of its concentration in the culture medium
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a - M S H a - M S H ( 2 - 1 3 ) a - M S H ( 3 - 1 3 ) a - M S H (4 - 1 3 ) a - M S H ( 5 - 1 3 )
Fig. 3.6. Relative binding or activity (log scale) of a-MSH fragments lacking N- 
terminal amino acids. Individual bars represent single experiments: binding 
affinity, white; tyrosinase activity, cross-hatched; melanin biosynthesis, black
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a - M S H
( 1- 1 0 )
a - M S H
( 1 - 1 1 )
a - M S H
( 1 - 1 2 )
a - M S H
Fig. 3.7. Relative binding or activity (log scale) of a-MSH fragments lacking C- 
terminal amino acids. Individual bars represent single experiments: binding affinity, 
white; tyrosinase activity, cross-hatched; melanin biosynthesis, black
Table 3.1. Dissociation constants and EC50 values for a-MSH fragments. Each




















































































Table 3.2. Affinity and activity constants of a-MSH fragments relative to a-MSH
Binding Tyrosinase Melanin
rNle4,D-Phe7la-MSH 10.2 33.9 7.4
a-MSH 1.0 1.0 1.0
Ac-a-MSH^., ^ -NH, 1.06 0.64 0.41
Ac-a-MSH^., ^ -NH, 0.11 0.20 0.18
Ac-a-MSH^., ^ -NH, 0.53 0.91 0.84
Ac-a-MSH^_, ^ -NH, 0.0016 0.001 0.0006
A c-a-M SH n?rNH, 0.85 0.31 0.03
Ac-a-MSHn i , ^ -NH, 0.05 0.05 0.006
Ac-a-MSHn m-NHj 0.0087 0.013 0.004
3.3. Binding affinity and biological activity of alanine analogues of a-MSH
This group of peptides contains thirteen analogues in which one amino acid has 
been replaced by alanine in order to study the influence of the amino acid side- 
chains and functional on receptor binding and biological activity.
3.3.I. Receptor Binding
Dissociation constants for the analogues were obtained as above (Table 3.3.). The 
affinities relative to a-MSH are shown in Table 3.4.. Alanine replacements in the 
N-terminal (amino acids 1-3) region did not significantly affect the affinity of the 
peptide. Within the 4-9 core of the peptide, alanine substitution of the amino acids 
Met4, His6, Phe7, Arg8 and Trp9 lead to a significant drop in the binding to the 
receptor with the relative affinities of 0.0073, 0.012, 0.002, 0.00048 and 0.0005, 
respectively. Replacement of Glu5 by alanine gave a peptide with an affinity that
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was not significantly different from a-MSH. In the C-terminal part of the hormone 
(amino acids 10-13), replacement of Gly10, Lys11 and Val 13 gave peptides with 
affinities not significantly different from a-MSH whereas substitution of the Pro12 
yielded a peptide with significantly lower affinity (9.6% of a-MSH) (Fig. 3.8.).
3.3.2. Tyrosinase Assay
EC50 values are given in Table 3.3.; data relative to a-MSH is shown in Table 3.4.. 
Alanine substitution in either terminal region of the hormone (amino acids 1-3 or 
10-13) did not significantly affect its biological activity. Within the peptide core, 
replacement of Glu5, His6 and Gly10 could be made without significant loss of 
activity. Alanine substitution of Met4, Phe7, Arg8 and Trp9 lead to significantly 
higher EC50 values and gave peptides with relative activities of 0.017, 0.0038, 0.01 
and 0.008 respectively (Fig. 3.8.).
Table 3.3. Kd and EC50 values for alanine analogues of a-MSH. Each value is the 







































































































Fig. 3.8. Relative affinity or activity of alanine-substituted analogues of a-MSH 
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[Alan ]a-MSH 0.57 0.25
[Ala12]a-MSH 0.096 0.23
[Ala13]a-MSH 1.14 1.25
3.4. D-Phe7 analogues of a-MSH
D-amino acid analogues of a-MSH, in particular D-Phe7 analogues have been 
studied following observations that the bioactivity of a-MSH is increased when 
racemisation occurs. [Nle4,D-Phe7]a-MSH has been reported to be a prolonged
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acting, 'superpotent' analogue of the hormone (Sawyer et al., 1982). Due to its 
greater stability and ease of radioiodination it is now used as a standard 
comparison throughout the literature.
3.4.1. Receptor binding
Estimates of the dissociation constants are shown in Table 3.5. ; the relative affinity 
is given in Table 3.6.. The binding affinity of [Nle4,D-Phe7]a-MSH is 10 times 
higher than that of a-MSH. The receptor binding of [Nle4, Asp5,D- 
Phe7,Lys10,Argn ]a-MSH and [Nle4,D-Phe7,D-Trp9]a-MSH is in the same range, 
being significantly higher than a-MSH (6.38 and 7.98, respectively), but not 
significantly different from [Nle4,D-Phe7]a-MSH (Fig. 3.9.).
3.4.2. Tyrosinase assay
Both [Nle4,D-Phe7]a-MSH and [Nle4>Asp5,D-Phe7,Lys10,Argn ]a-MSH showed a 
significantly higher activity than a-MSH with their respective EC50 values being 
33.1 and 39.3 times higher than of the native hormone. [Nle4,D-Phe7,D-Trp9]a- 
MSH was significantly different from a-MSH (p<0.05) with 12.2 times its activity 
(Fig. 3.9.).
3.4.3. Melanin assay
[Nle4,D-Phe7]a-MSH and [Nle4* Asp5,D-Phe7,Lys10,Argn ]a-MSH were
significantly more active than a-MSH in this assay. [Nle4,D-Phe7,D-Trp9]a-MSH 










Fig. 3.9. Relative affinity or activity of D-Phe7 analogues o f a-MSH (log scale). 
Individual bars represent single experiments: cross-hatched, affinity; black, 
tyrosinase activity. (1) = [Nle4,D-Phe7]a-MSH, (2) = [Nle4,Asp5,D-Phe7,Lys10, 
Argn ]a-MSH, (3) = [Nle4,D-Phe7D-Trp9]a-MSH, (4) = a-MSH.
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Table 3.5. Dissociation constants and EC50 values of D-Phe7 analogues of a-

















































3.5. Cyclic analogues of a-MSH
Two cyclic a-MSH derivatives containing a disulfide bridge between positions 4 
and 10 have been assayed for receptor binding and biological activity. Also, the 
linear analogue [Cys4,Cys10]a-MSH is included in this section to allow a 
comparison of the relative affinities and activities of the analogues with a molecule 
of the same structure. It was also attempted to produce a cyclic analogue of 
[Nle4, Asp5,D-Phe7,Lys10,Argu ]a-MSH with a lactam ring between positions 5 and 




The dissociation constants are given in Table 3.7.\ data relative to a-MSH are 
shown in Table 3.8.. The affinity of [Cys4,Cys10]a-MSH (0.06%) and 
[Cys4,Cys10]a-MSH (0.24%) were both significantly different from a-MSH, but 
they were also significantly different from each other. The binding of Ac-[Cys4,D- 
Phe7, Cys1 °]a-MSH(4.2 3)-NH2 was three times higher than that of the natural ligand 
and thus significantly different from a-MSH and the other two peptides in this 
group (Fig. 3.10.).
3.5.2. Tyrosinase Assay
The EC50 values are shown in Table 3.7. and the activity relative to a-MSH in 
Table 3.8.. The tyrosinase stimulating activity of [Cys4,Cys10]a-MSH and 
[Cys4, Cys10]a-MSH was not significantly different from that of a-MSH, whereas 
they were different from Ac-[Cys4,Cys10]a-MSH(4 .13 )-NH2. The biological activity 
of Ac-[Cys4,D-Phe7,Cys1 °]a-MSH(4.13 )-NH2 was significantly different from a- 
MSH with p<0.05 (Fig. 3.10.).
3.5.3. Melanin Assay
Activity data are shown in Tables 3.5.1. and 3.5.2.. The biological activity of 
[Cys4,Cys10]a-MSH and [dys4,Cys10]a-MSH was not significantly different from 
a-MSH in this assay; Ac-[Cys4,D-Phe7,Cys^Ja-MSH^^-NHj had not been 
tested.
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1 2 3 4
Fig. 3.10. Relative affinity or activity of linear and cyclic analogues of 
[Cys4,Cys10]a-MSH (log scale). Individual bars represent single experiments: 
cross-hatched, binding affinity; white, tyrosinase stimulation; black, melanin 
biosynthesis. (1) = a-MSH, (2) = [Cys4,Cys10]a-MSH, (3) = [Cys^Cys10]a-MSH, 
(4) = [Cys4, D-Phe7, C y s^ a -M S H ^ ^ .
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Table 3.7. Dissociation constants and EC50s of cyclic a-MSH analogues. Each







































r Cys4, Cys10]a-MSH 0.06 0.63 0.28




3.6. Other MSH peptides
Both desacetyl-a-MSH and the free acid have been tested, the desacetyl peptide, 
which occurs naturally in dogfish, mainly for comparison with the MC3 receptor. 
Yr MSH has not been tested for binding to this receptor before; other y-MSH 
peptides have not been tested as they are expected to exhibit similar or lower 
affinity due to their extended C-terminus which might not be recognised by the 
receptor.
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3.6.1. Competitive Binding/Tyrosinase Assay
There was no significant difference in binding or tyrosinase stimulating activity 
compared to a-MSH. The dissociation constant was estimated to be 
1.68±0.598xl0'8M (n=3). The EC50 was determined as 7.18±5.19xlO*10M (n=3). 
Desacetyl-a-MSH and Yj-MSH have only been tested in the binding assay. Their 






Binding Affinity and Biological Activity of a-MSH 
Derivatives in B16 Mouse Melanoma Cells
Although a number of the peptides including the terminal deletion fragments and 
the analogues of [Cys4,Cys10]a-MSH described here have already been tested for 
their affinity or activity in various reptilian and mammalian bioassays (for a review 
see Eberle, 1988), their activities have not been systematically studied in relation to 
their receptor binding affinity. Also, numerous single and multiple amino acid 
replacements have been made within the sequence, but a systematic investigation 
into the role of individual amino acid side-chains in receptor-ligand interaction has 
not yet been made. Direct comparison of binding affinity and biological activity 
allows an estimate of the intrinsic efficacy of the analogues. Tyrosinase activity and 
melanin biosynthesis assays have been carried out in parallel for some of the 
peptides tested. Results from both assays were generally in good agreement with 
each other, but because of the greater experimental error associated with the 
melanin biosynthesis assay, it was thought that, although more convenient, it is less 
valuable than the tyrosinase assay in determining the biological response of the 
cells.
4.1. Binding of [125I-Tyi^,Nle4,D-Phe7]a-MSH
Binding isotherms with the mono-iodinated a-MSH derivative [125I-Tyr2,Nle4,D- 
Phe7]a-MSH showed that this ligand bound specifically to the cell surface receptor 
(Fig. 3.2. and 3.3.). The dissociation constant was estimated to be
0.48nM±0.08nM. This is in agreement with values previously obtained with the 
same assay in our laboratory (Erskine-Grout, 1993). The population of receptors is 
believed to be homogeneous as shown by Scatchard analysis (Scatchard, 1949). 
Their number varied from 5,000 to 20,000, but the variable number of binding sites 
did not affect the binding affinities of the ligands.
a-MSH bound to the receptor with an affinity of 20.6±5.31nM. This is a slightly 
lower affinity than reported by Eberle (1988), who reported a value of 1.3nM for 
a-MSH. This disagreement might be due to different experimental conditions used 
(incubation for 3h at 15°C, use of MEM medium). It is not likely to be caused by 
the use of a different strain of B16 cells as they would be expected to express a 
very similar receptor, although there are some reports of heterogeneity of the a- 
MSH receptor among B16 murine melanoma cell subclones (Solca et al., 1991).
4.2. Influence of terminal amino acids
Since the structure-activity relationships of a-MSH were first studied and it was 
found that the pentapeptide sequence a-MSH(6.10) displayed weak but distinct 
pigment-dispersing activity (Schwyzer and Li, 1958), it has been known that 
neither of the termini of the peptide are crucial for the peptide's biological action. 
The unimportance of the N-terminus has been established in a-MSH fragments 
(see Eberle, 1988; p336) and cyclic analogues (Knittel et al., 1983); data from 
Eberle comparing several assays, however, suggest that the terminal amino acids 
are more influencial in the Rcma pipiens melanophore assay than in any other 
assay. The C-terminal amino acids 10-13 are clearly more important than the N- 
terminal residues even though biological activity is retained when they are omitted. 
There is some evidence that the C-terminal tripeptide a -M S H ^ ^  contains a 
"secondary message sequence" as it was shown to display pigment dispersing 
activity (Eberle and Schwyzer, 1975) as well as some of the CNS activities of a-
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MSH, such as anti-inflammatory action (Hiltz et al., 1991). Other studies,
however, indicate that the presence of the tripeptide does not significantly increase
the biological activity of some a-MSH fragments (Hruby et al., 1987; Sawyer et
al., 1991). Eberle suggested that as a-MSHp.13) exhibited about the same activity
as the central hexapeptide a-MSH(5.10), but the dipeptides Ac-Trp-Gly-OH and
Ac-Pro-Val-OH were inactive, Lys11 might play a key role in the biological activity
of this C-terminal a-MSH fragment. Studies on the influence of C-terminal amino
• ■ " —
acids on the activity of fragments of [Cys4,Cys10]a-MSH have shown that while 
Val13 did not contribute to the biological activity of the peptide, loss of the proline 
resulted in a 10-100 fold drop in activity in three different assays, and subsequent 
omission of Lys11 reduced the activity a further 5-20 fold (Cody et al., 1984).
In the work reported here, consecutive deletion of amino acids 1-3 from the N- 
terminus of a-MSH gave three peptides whose biological activity was not 
significantly different from a-MSH or from each other, but the binding affinity of 
Ac-a-MSH(3 .13 )-NH2 was significantly different from both a-MSH and Ac-a- 
MSH^^-NHj, but not from Ac-a-MSH(4_x 3)-NH2. As Ac-a-MSH^^j-NHj 
showed similar biological action to a-MSH, the N-terminus is obviously not 
required for either receptor binding or biological activity (Fig. 3.6., 3.7.). The 
results obtained with Ac-a-MSH(2.13 )-NH2 and Ac-a-MSHp.^-NH^ however, 
suggest, that if the N-terminus is present, the tyrosine in position 2 has a role in 
interacting with the receptor, probably in a non-specific manner due to its relative 
hydrophobicity as compared to serine. This would also explain why the affinity of 
the analogue [Nle4,D-Phe7]a-MSH (Kd=2.02nM) is increased upon radioiodination 
([125I-Tyr2,Nle4,D-Phe7]a-MSH: Kd=0.48nM). These results are generally in 
agreement with results reported in the literature (see Eberle, 1988).
Ac-a-MSH(1.12)-NH2 did not have a significantly different binding affinity or 
tyrosinase stimulating activity from a-MSH, but values from the melanin assay
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showed a statistically significant difference to the natural ligand. As this is the 
difference in biological activity assayed by tyrosinase or melanin assay, it is likely 
to be due to the experimental technique rather than to a genuine difference in 
activity. Ac-a-MSH^.^-NHj showed only 5% of the binding and tyrosinase 
stimulating activity and 0.6% of the melanin biosynthesis compared to a-MSH. 
Finally, Ac-a-MSH^.^-NHj with approximately 1% of the affinity and tyrosinase 
stimulating activity and 0.3% of the biological activity in the melanin biosynthesis 
assay, showed significantly different receptor binding from Ac-a-MSH^ 
but there was no significant difference in biological activity between the two 
fragments. These results indicate that the proline in position 12 might be the key 
residue in this terminal end of a-MSH, rather than the Lys11 as previously 
suggested (Eberle, 1988). The data is in accordance with findings obtained by 
Cody et al. (1984) for fragments of [Cys4,Cys10]a-MSH.
4.3. Influence of single amino acid replacement
Single amino acid replacement by alanine is a technique that has previously been 
employed in the investigation of the ligand receptor interaction of physiological 
peptides (Beck-Sickinger et al., 1990; O'Donnell et al., 1991; Peeters et al., 1992). 
It provides insight into the importance of individual amino acid side-chains for the 
interaction with the receptor while maintaining the stereochemistry of the peptide 
backbone; alanine is the shortest amino acid this can be obtained with. For a- 
MSH, the importance of the terminal amino acids on its affinity and activity has 
been widely studied (see Eberle, 1988 and section 4.2.), but the importance of 
individual residues within the core sequence has not been investigated 
systematically using both activity and binding assays in a mammalian cell line.
Substitution of the N-terminal amino acids Ser1, Tyr2 and Ser3 did not significantly 
affect the binding affinity or biological activity of a-MSH. This is in agreement
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with observations made with the a-MSH fragments, Ac-a-MSH^^-NH^ Ac-a- 
MSH(3 .13 )-NH2 and Ac-a-MSH^^-NHj (see section 4.1.).
Within the peptide core, amino acids 4-9, alanine replacement generally decreased 
the affinity and/or activity of the hormone. Substitution of the glutamic acid 
residue in position 5, however, unexpectedly led to a peptide with similar 
biological properties to a-MSH. In spite of having a charged side-chain, this result 
suggests that it does not participate in the interaction with the receptor. Previous 
studies have shown that although replacement of Glu by Gin reduced the activity 
of a-MSH in the frog skin bioassay 20 times, this substitution was possible 
without further loss of activity in a-MSH(5.10) (Blake et a l, 1970). Attachment of 
large groups to the side-chain of Glu was also reported to reduce activity (Eberle, 
1988). Studies by Al-Obeidi et al. (1989a,b) were carried out with linear and cyclic 
analogues of [Nle4,D-Phe7]a-MSH, Ac-psile4,Glu5,D-Phe7,Lys10,Gly^Ja-MSH^ 
13)-NH2and Ac-[Nle4, Asp3,D-Phe7,Lys10, Gly11]a-MSH(4 .13 )-NH2, and showed that 
lactam cyclisation of these peptides through the side-chains of Glu5 or Asp5 and 
Lys10 is possible without loss of activity in the frog skin assay and resulted in even 
higher activities in the lizard skin assay. Hence, amidation and conformational 
restraint at residue 5 does not affect the biological response of the hormone. 
[Ala4]a-MSH showed significantly reduced binding and biological activity 
compared to a-MSH. Methionine could however be replaced isosterically by 
norleucine (Sawyer et al., 1982; Siegrist et al., 1988) without loss of affinity or 
activity. Substitution of methionine with cysteine in linear and cyclic 
[Cys4,Cys10]a-MSH derivatives is also possible without affecting the properties of 
the peptide (Sawyer et al., 1980; Eberle, 1988; section 3.5.). Oxidation of the 
residue to Met(O) or Met(02) leads to almost complete loss of binding affinity and 
biological activity (Eberle et al., 1978; Siegrist et al., 1988). Introduction of a 
tyrosine residue at this position in the a -M S H ^^  and a -M S H ^^  analogues gave 
peptides with significantly less activity in both the frog and the lizard skin bioassay,
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which were only partial agonists in the Cloudman S91 adenylate cyclase assay 
(Wilkes et al., 1984).
Introduction of an alanine residue in position 6 decreased the binding affinity 
significantly to 0.012 times that of a-MSH whereas there was no difference in the 
biological activity (0.17) compared to the native ligand. This suggest that full 
receptor binding might not be required to trigger the biological response.
Alanine substitution in positions 7, 8 and 9 clearly affected the binding affinity and 
biological activity the most. While replacement of Phe7 by alanine affected binding 
and activity to the same extent (relative values being 0.002 and 0.0038), exchange 
of Arg8 and Trp9 seemed to reduce the binding affinity more than the biological 
activity (0.00048 vs. 0.01 and 0.0005 vs. 0.008, respectively). Previous studies 
have shown that replacement of Phe7 by its D-isomer is possible while any other 
substitution in position 7 and 8 significantly decreases binding and activity of the 
hormone (Eberle, 1988). Introduction of a D-Trp9 is also possible without 
affecting the peptide (section 3.4.). Trp9 could also be replaced by 
pentaphenylalanine (van Nispen et a l, 1970) and leucine (Eberle and Schwyzer, 
1979) and retain a relatively high amount of activity in the frog skin assay. 
Attachment of a 2-nitro-4-azidophenylsulphenyl (Naps) photoaffinity label to the 
tryptophan led to a peptide with slightly higher activity than a-MSH (Scimonelli 
and Eberle, 1987). It seems that this amino acid can generally be replaced by other 
aromatic residues, or non-aromatic amino acids of a certain size and lipophilicity. 
Any substitution is likely to affect affinity more than activity.
In the C-terminal part of the peptide, substitution of the glycine in position 10 did 
not affect the biological properties of the peptide. This might be due to the 
structural similarity of the two amino acids, although alanine is expected to restrict 
the conformational freedom of the peptide backbone. Previously, it has been
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suggested that glycine acts as a spacer rather than being an important residue in 
itself (Medzihradsky, 1976). Introduction of other residues such as cysteine in 
[Cys4,Cys10]a-MSH (Sawyer et al., 1980; Eberle, 1988) or lysine in Ac- 
[Nle4,Glu5,D-Phe7,Lys10,Gly11]a-MSH(4.13 )-NH2 and Ac-[Nle4,Asp5,D-Phe7,Lys10, 
Gly11]a-MSH(4.13)-NH2 (Al-Obeidi et al., 1989a,b) appears to be possible in both 
linear and cyclic analogues without major effects on the peptide's action.
[Alan ]a-MSH had approximately the same affinity and activity as the native 
hormone. This is in contradiction to earlier results which suggested that the basic 
side-chain of Lys11 might be important for the interaction with the receptor, and 
replacement with serine or glutamic acid decreased the biological activity by a 
factor o f20-40 (Eberle, 1988). It was shown in our laboratory that it is possible to 
attach a photoaffinity label, 4-(l-azi-2,2,2-trifluoroethyl)benzoic acid (ATB), onto 
the lysine without significant loss of affinity (Ahmed et al., 1992). Replacement by 
arginine (section 3.4.) and glycine (Al-Obeidi et al., 1989a,b) is also possible 
without affecting the biological properties of the molecule.
Substitution of the proline in position 12 with D-proline, norvaline or glycine has 
been reported to significantly decrease the biological activity of a-MSH in several 
reptilian bioassays and the Cloudman S91 tyrosinase assay (Eberle, 1988). 
Replacement by alanine reduced the binding affinity to 10% in B16 melanoma cells 
while the biological activity was not significantly lower than that of the native 
hormone.
Substitution of Val13 was possible without affecting the affinity and activity of the 
peptide; earlier findings suggested that this residue can be replaced as long as it 
remains lipophilic (Eberle, 1988).
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4.4. Cyclic a-MSH analogues
Cyclic, conformationally constrained peptide derivatives are valuable tools in the 
study of structure-conformation relationships. They adopt a more defined range of 
conformation than linear peptides and are thus more amenable to conformational 
analysis by NMR spectroscopy, circular dichroism or IR spectroscopy (Hadley, 
1988). Also, they possess an energetic advantage compared to linear molecules as 
they do not have to adopt a biologically active conformation prior to receptor 
binding. Two ways of introducing a ring-structure into a peptide molecule have 
been attempted for a-MSH: formation of a disulfide bridge and lactam cyclisation. 
Both these attempts have been made for a-MSH. The first cyclic a-MSH analogue
j ■ \
to be described was [Cys4,Cys10]a-MSH (Sawyer et al., 1982), which was 
originally reported to be 10,000 times as active as a-MSH in the frog skin 
bioassay. Later, this value had to be revised and it was found to exhibit a 10 fold 
higher activity in this assay (Eberle, 1988). The reason this particular structure was 
chosen was that it seemed to stabilise a reverse turn of the peptide backbone 
between positions 6 and 9, a conformation that had been proposed after the 
discovery of [Nle4,D-Phe7]a-MSH as a superpotent a-MSH analogue (Sawyer et 
al., 1980). The D-Phe7 replacement appeared to favour the P-tum conformation in 
this part of the active side of the peptide. In [Cys4,Cys10]a-MSH, both the putative 
active sites, residues 6-9 and 11-13, were left unchanged, and the amino acid 
substitutions made in position 4 and 10 can be considered pseudoisosteric. A 
number of other substitutes for position 4 were tested in cyclic compounds (Lebl et 
al., 1984a,b), and while replacement of Cys with D-Cys or 3-mercapto propionic 
acid is possible without significant loss of activity, introduction of mercapto acetic 
acid reduces the biological activity of the cyclic compound dramatically. This is 
believed to be due to the reduced ring size in this molecule compared to 
[Cys4,Cys10]a-MSH. Influence of the C-terminal amino acids (11-13) was then 
investigated and it was found, that V al13 is not required, but there is a drastic loss
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of activity following the loss of Pro12, with a less dramatic loss after subsequent 
omission of Lys11 (Cody et al., 1984). This is in agreement with our findings for 
linear a-MSH fragments (see section 4.1.). Nearly the same pattern can be 
observed in cyclic fragments containing the D-Phe7 residue, although omission of 
Pro12 and Lys11 in the D-Phe7 form clearly affected the peptide less than in the L- 
Phe7 analogue (Cody et al., 1988).
No receptor binding data has been reported for any of the cyclic compounds so far, 
nor have they been compared to their linear analogues. In the B16 murine 
melanoma cells, both linear and cyclic [Cys4,Cys10]a-MSH showed a significantly 
lower affinity for the receptor (see section 3.5.); their affinities were also 
significantly different from each other with the linear analogue possessing only 
23% of the binding affinity of the cyclic peptide. In the tyrosinase and melanin 
assay, however, there was no difference between the two forms. This indicates that 
while the cyclic form is stable at 0-4°C, the disulfide bridge might be degraded at 
37°C giving the linear peptide. A D-Phe7 analogue, Ac-[Cys4,D-Phe7,Cys10]a- 
MSH(4_13)-NH2 was also tested and it showed approximately the same biological 
properties as [Nle4,D-Phe7]a-MSH with its relative affinity and tyrosinase 
stimulating activity being 3.09 and 10.5, respectively, compared to a-MSH. The 
increase in activity observed here is interesting considering that the cyclisation 
itself is said to stabilise the reverse turn conformation of the peptide backbone 
(Sawyer et al., 1982); possibly the D-amino acid further stabilises any existing 
structures, or the molecule was actually present in an opened form, which then 
profits from the introduction of the D-Phe residue. The observation is in agreement 
with literature values for the bioactivity of D-Phe substituted analogues of 
[Cys4,Cys10]a-MSH (Cody etal., 1988).
Cyclic lactam analogues of a-MSH have been made in two different positions. The 
first cyclic lactam compounds were Ac-[Nle4,D-Om5,Glu8]a-MSH(4.n)-NH2 and
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its D-Phe7 analogue, giving a 17-membered ring (Sugg et al., 1988). The choice 
of this particular ring structure was based on predictions by Nikiforovich et al. 
(1981) that the side-chains in positions 5 and 8 are likely to form a salt bridge, and 
[D-Om5,Glu8] was adapted for synthetic convenience rather than the [D- 
Glu5,Om8] form. The L-Phe derivative is slightly more potent than the linear Ac- 
[Nle4]a-MSH(4 .11)-NH2 analogue, but less active in the lizard skin assay. The D- 
Phe7 derivative is less active than the L-Phe form in both assays. NMR data 
obtained with these analogues suggested that close proximity of the His-Phe-Arg 
side-chains seems to be favourable for triggering the biological response.
Lactam formation between positions 5 and 10 in Ac-[Nle4,Glu5,D-
P he^ys^G ly1'ja-M SH^^-NHj and Ac-[Nle4,Asp5,D-Phe7,Lys10,Gly1 ]]a-
MSH(4_13)-NH2 is possible whilst retaining the biological properties of the peptide
(Al-Obeidi et al., 1989b). This ring structure contains 23 atoms; the C-terminus is
not required for the biological action of these derivatives as experiments with the
4-10 form have shown. The influence of the N-terminal amino acids has not been
tested, but it is possible to add fatty acid to the N-terminus of the Ac-[Asp5,D- 
 »
Phe7,Lys10]a-MSH(5.10)-NH2 analogue which led to peptide conjugates that exhibit 
10-100 times the biological activity of a-MSH in the Cloudman S91 tyrosinase 
assay. Hexanoyl- and decanoyl-analogues show approximately the same activity as 
a-MSH, and myristoyl- and palmitoyl-derivatives 1% of its activity in the lizard 
skin bioassay (Al-Obeidi et al., 1992).
4.5. Influence of D-amino acid replacements within the peptide core
Investigations into the stereochemistry of the a-MSH backbone were made very 
early on after the discovery of the peptide structure in 1957 (Harris and Lemer, 
1957) together with the observation that partial racemisation increased the 
bioactivity of the hormone in some bioassays (Lee and Buettner-Janusch, 1963). A
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systematic study was carried out in the 1960s by Yajima et al., where they 
investigated the influence of D-amino acid replacements within the oc-MSH(6_10) 
pentapeptide using an in vitro frog skin assay. The His-D-Phe-Arg-Trp-Gly 
fragment showed a greater activity than the analogue containing only L-amino 
acids (Yajima et al., 1966). Introduction of a second D-residue is only possible in 
position 9 (Yajima et al., 1967). D-His-D-Phe-Arg-Trp-Gly exhibited only weak 
MSH activity. Replacement of arginine with its D-isomer made the peptide 
fragment inactive contradictory to earlier findings that it was as active as the all D- 
form. Introduction of a D-Phe residue into this molecule seemed to restore its 
bioactivity, but it did not show the prolonged activity observed with the D-Phe, L- 
Arg derivative (Yajima et al., 1965, 1967). Substituting more than two amino 
acids by their D-isomers as in D-His-D-Phe-D-Arg-Trp-Gly and His-D-Phe-D- 
Arg-D-Trp-Gly gave peptides with no MSH activity, but weak inhibitory effects 
when administered at the same time as the L-L-L-L-pentapeptide (Yajima et al.,
1965). The all D-isomer showed even stronger inhibitory effects (Yajima et al.,
1966).
After it was established that [Nle4,D-Phe7]a-MSH as a more potent, prolonged 
acting analogue of a-MSH, which is more resistant to enzymatic degradation and 
provides the opportunity for radioiodination (Sawyer et al., 1980), several other 
studies have been carried out concerning the bioactive conformation of a-MSH. 
Systematic studies by Sugg et al. (1986) investigated the effects of D-amino acid 
substitution on the Ac-[Nle4]a-MSH(4.n)NH2 derivative using the frog skin assay 
and their results are more or less in agreement with those by Yajima et al., 
although the antagonistic effects reported in the earlier studies have not been 
confirmed. In addition to the biological experiments, Sugg et al. used NMR studies 
to elucidate the conformation possibly recognised by the receptor. They proposed 
a left-handed turn in the 6-9 portion of the peptide with a gauche conformation of 
the amino acid side-chains as the most active conformation.
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Recognising the key role of Phe7, Wilkes et al. (1986) then made a range of 
changes to this residue in the Ac-[Nle4]a-MSH(4.11)-NH2 analogue in order to 
investigate the influence of this particular amino acid. They replaced phenylalanine 
by tyrosine, p-nitrophenylalanine, alanine and glycine as well as by their 
corresponding D-amino acids. In all cases, except when substituting with alanine, 
the D-isomers were more potent than the L-forms in both the frog and the lizard 
skin assay, but none of them was as potent as Ac-[Nle4]a-MSH(4.11)-NH2 or Ac- 
[Nle^D-Phe^a-MSH^^nj-NHj in those assays. A further study by this group 
investigated the replacement by phenylglycine (Pgl) and 1,2,3,4- 
tetrahydroisoquinoline (Tic) and their D-isomers, but none of them was more 
potent than Ac-p'fle4]a-MSH(4_11)-NH2 or Ac-[Nle4,D-Phe7]a-MSH(4.11)-NH2, 
except Ac-[Nle4,Pgl7]a-MSH(4_11)-NH2 in the frog skin assay. Replacement by D- 
Pgl led to a major reduction in activity in both frog and lizard bioassays whereas 
introduction of Tic affected the results in lizard skin significantly more than those 
from the frog skin assay (Hruby et al., 1988). Summarising these findings it is 
obvious that introducing these types of conformational constraints in position 7 is 
not favourable for the biological activity of the peptide. Binding experiments using 
PHj-Ac-fNle^D-Phe^a-M S^nj-NH (Panasci et al., 1987) and [125I-
Tyr2,Nle4,D-Phe7]a-MSH (Siegrist et al., 1988) revealed that the D-Phe analogues 
also exhibit greater binding affinities than a-MSH itself. Eberle (1988) has 
suggested that this phenomenon might be caused by nearly ''irreversible" binding to 
the receptor.
Introduction of the D-amino acid in position 7 increased the activity of all a-MSH 
analogues reported in the literature, except for a cyclic lactam analogue of Ac-a- 
MSH^hj-NHj, [D-Om5,Glu8]a-MSH(4.11)-NH2, where the L-Phe7 analogue is 
more potent in the frog skin assay and in the lizard skin assay (Sugg et al., 1988).
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Investigations into the influence of the stereochemistry of a-MSH on its other 
functions have not systematically been made, but there are reports by Beckwith et 
a l (1989), that while a-MSH enhances memory reactivation in rats with 
hypothermia-induced amnesia, Ac-[Nle4,D-Phe7]a-MSH(4.10)-NH2 had an amnesic 
effect in some of the experiments while acting like a-MSH in some others. The 
cyclic compounds Ac- [dy s4, Cys1 °] a-MSH^ x and Ac-[Cys4,D-
Phe^Cys^Ja-MSH^oj-NHj were also shown to be less active than a-MSH in 
these assays.
In this work, results obtained with D-Phe7 analogues of a-MSH were generally in 
agreement with findings of other groups. [Nle4,D-Phe7]a-MSH showed a 10.2 
times higher binding affinity compared to a-MSH. Results by Siegrist et a l  
previously suggested a 6.2 times stronger receptor binding (Siegrist et a l , 1988). 
Its biological activity in the tyrosinase and melanin assay was found to be 33.9 and 
7.4 times that of the native hormone, respectively. This is also in the range of 
values found in the literature (compare Eberle, 1988). Whether the introduction of 
the D-Phe7 residue is involved in stabilising a type of reverse turn as suggested by 
Hruby et al. (1988), or indeed any other structure favoured by the receptor, is not 
fully clear. A three-dimensional model for the receptor would facilitate further 
investigation of this problem.
[Nle4,Asp5,D-Phe7,Lys10,Argn ]a-MSH is a full-length derivative of Ac- 
[Nle4, Asp5,D-Phe7,Lys10]a-MSH(4.11)-NH2, which was first described by Al-Obeidi 
et a l (1989a) and is of interest because lactam cyclisation is possible between 
positions 5 and 10. It was hoped to restore full activity of the peptide by including 
both terminal ends. The short linear peptide was reported to exhibit approximately 
the same activity as a-MSH in the frog skin assay and 8 times the activity in the 
lizard skin assay, but no binding data is available. In our study, the full-length 
linear analogue showed similar affinity and activity to the originally reported
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[Nle4,D-Phe7]a-MSH ligand with its relative potencies being 6.38, 39.1 and 10.1 
in the three assays, respectively. The additional conformational restraint imparted 
on the peptide by the introduction of the lysine residue instead of the glycine in 
position 10 did obviously not significantly affect the properties of the peptide; an 
effect that could be observed with the substitution of glycine by alanine in a-MSH 
as well (see section 3.3.).
Replacement of L-Phe by D-Phe in position 7 of a cyclic analogue, Ac-[Cys4,D- 
Phe7,Cys10]a-MSH(4 .13 )-NH2, increased the binding affinity and biological activity 
of the peptide compared to a-MSH and linear and cyclic [Cys4,Cys10]a-MSH, 
with the potency of the peptide now being similar to [Nle4,D-Phe7]a-MSH. This 
suggests that this cyclised compound is a very good model for the bioactive 
conformation of a-MSH, although it is possible that the disulfide bridge is actually 
opened once the peptide is exposed to the cellular enzymes (see section 4.3.).
[Nle4,D-Phe7,D-Trp9]a-MSH, synthesised in analogy to Ac-[Nle4,D-Phe7, D- 
Trp9]a-MSH(4_11}-NH2 first described by Hruby's group (Sugg et al., 1986), had 
not previously been assayed in any mammalian pigment cell assays. It showed 
biological properties similar to [Nle4,D-Phe7]a-MSH in the binding and the 
tyrosinase assay; stimulation of melanin biosynthesis was not determined. Its 
relative potency is close to [Nle4,D-Phe7]a-MSH with 7.98 times the affinity and 
12.2 times the tyrosinase stimulating activity of a-MSH. There is no evidence that 
additional introduction of the D-Trp further increases the biological activity as 
compared to [Nle4,D-Phe7]a-MSH in mammalian melanoma cell assays.
4.6. Other MSH peptides
The binding of a-MSH with a free N- or C-terminus was also studied. For a- 
MSH-OH, both binding affinity and biological activity were studied; both were not
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significantly different from the naturally occurring ligand. This is in agreement with 
earlier findings that a free carboxyl group on the C-terminus did not affect the 
melanotropic activity of the peptide in the frog skin assay (Medzihradsky et al., 
1976). The desacetyl form of a-MSH naturally occurs in dogfish, but also in 
mammals. In this study, only the binding affinity of this peptide was tested, mainly 
to compare its affinity to that on the MC3 receptor. With a dissociation constant of 
15.0nM, there was no significant difference in binding affinity compared to a- 
MSH. This peptide was reported to exhibit only marginally less activity than a- 
MSH in most bioassays except the frog skin assay, were it was ten times less active 
than the endogenous ligand. Its affinity was previously described as 1.3nM (Eberle, 
1988); a value that was found for a-MSH in the same study as well. It seems that 
both terminal groups of the peptide are of no importance for the binding and 
biological action of the peptide at least in mammalian melanocytes, and also in 
most reptilian and amphibian melanophores (except Ranapipiens).
Comparatively little data has been published on the effects of y-MSH peptides on 
melanophores and melanocytes. They are generally found to exhibit very low 
activities. yr MSH shows the highest activity of all y-MSH peptides in the Rana 
pipiens bioassay. Interestingly, this activity is increased upon acetylation. Only pro- 
yj-MSH showed a higher activity, but as the material was gained from pituitary 
extracts, this is likely to be caused by contamination with other MSH/ACTH 
peptides. None of the synthetic y-MSH peptides displayed more than 0.1% of the 
activity of a-MSH in any of the assays, and it has therefore been claimed that this 
group peptides does not contribute to the pigmentary action of POMC peptides 
(Eberle, 1988). In our study, y^MSH bound approximately 100 times less strongly 
than a-MSH, which might explain the low bioactivity of the peptide. Due to a lack 
of material the biological activity of the compound was not tested.
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4.7. Summary
The systematic study of these peptides allows a good insight into the structure- 
activity relationships of the interaction of MSH peptides with the murine 
melanoma MCI receptor. Both terminal ends are not essential for binding or 
biological activity, however, the C-terminus appears to be more important than the 
N-terminus. The most important amino acids for both receptor binding and 
biological activity have clearly been identified as Met4, His6, Phe7, Arg8 and Trp9. 
Two of these amino acids can be replaced by their D-isomers; introduction of the 
D-Phe7 residue significantly increases the activity of the peptide. Substitution of 
the Trp9 by D-Trp9 does not further influence the properties of the peptide. The 
cyclic analogue, [Cys4,Cys10]a-MSH, exhibits a substantial amount of affinity and 
activity. If the cyclised form is actually present at the receptor binding site, then 
this together with the increased activity of the D-Phe7 analogue would support the 
hypothesis, that residues 6-9 form a kind of P-tum. In spite of having charged side- 
chains, the glutamic acid residue in position 5 and the lysine residue in position 11 
appear not to be important for binding affinity and biological activity. Residues in 
these positions might act as a spacer, but do not actively participate in the 
interaction of the hormone with its receptor.
Binding and biological activity data are generally in good agreement (Fig. 4.1.), 
but there are two analogues, [Ala6]a-MSH and [Ala12]a-MSH, where the affinity 
was significantly lower than that of the native hormone, but the biological activity 
as measured by the tyrosinase assay was not.
Data from the tyrosinase and the melanin assay were usually comparable, however, 
the biological activity of Ac-a-MSH(1.12)-NH2 was significantly different from a- 












Fig. 4.1. Tyrosinase stimulation (log scale) of all a-MSH analogues tested as a 




Binding of a-MSH, y-MSH and of Related Peptides to the 
MC3 Receptor
Time-course binding experiments have been carried out with mono-iodinated 
[Nle4,D-Phe7]a-MSH to establish the equilibrium time for receptor binding at 0- 
4°C and 37°C. This was studied at 0-4°C and 37°C to find the optimum 
conditions for the binding isotherm (see section 2.4.).
5.1. Time-course of receptor binding at 37°C
Preliminary experiments in 24-well plates show that the rate of binding increases 
over a period of lh. After reaching the maximum, the receptor binding decreases 
continuously as shown in Fig. 5. L.
5.2. Time-course of receptor binding at 0-4°C
Preliminary experiments in 24-well plates showed a continuously increasing rate of 
binding over a period of 6h. Measurement after 8h indicated that although the cells 
had started to detach from the plates, they had not reached maximum binding. 
Therefore, the incubation was carried out in multiwell filtration plates which allow 
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Fig. 5.1. Time-course of binding of [125I-Tyr2,Nle4,D-Phe7]a-MSH to the MC3 
receptor at 37°C. (■) total binding, ( • )  non-specific binding, (A) specific binding.
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Fig. 5.2. Time-course of binding of [^I-Tyr^Nle^D-Phe^a-MSH to the MC3 
receptor at 0-4°C. (■) total binding, ( • )  non-specific binding, (A) specific 
binding.
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5.3. Binding isotherm of [125I-Tyr2,Nle4,D-Phe7]a-MSH
Data obtained from four replicate isotherms was analysed as described in section
2.4.2.. An example of an isotherm is given in Fig. 5.3.. The dissociation constant 
was estimated to be 1.66nM. Scatchard analysis of the binding isotherm as 
described in section 2.4.2. indicated the presence of only one population of 
receptors (Fig. 5.4.). The number of receptors per cell varied from 50,000 to
10.000, generally decreasing with increasing passage number. Therefore, only cells 
with passage numbers 10-20 were used in the binding assays.
5.4. Binding of a-MSH, desacetyl-a-MSH, [Nle4,D-Phe7]a-MSH and Yj-MSH
The dissociation constants were obtained from the competition experiments as 
described in section 2.4.3.. The Kd for a-MSH was determined to be 2.07±1.18pM 
(n=4), that for the desacetyl-analogue 0.717±0.814pM (n=3). The receptor 
binding of Yj-MSH was not significantly different from that of a-MSH, with a 
dissociation constant of 3.24±2.15jjM. [Nle4,D-Phe7]a-MSH bound approximately 
100 times more strongly with a Kd of 21.5±17.3nM. Dissociation constants and 
binding relative to a-MSH are shown in Table 5.1.. An example for the 
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Fig. 5.3. Binding isotherm of [I25I-Tyr2,Nle4,D-Phe7]a-MSH to the MC3 receptor 
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Fig. 5.5. Binding of endogenous MSH peptides and [Nle4,D-Phe7]a-MSH to the 
MC3 receptor.
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Table 5.1. Dissociation constants (±SD; molar values) and relative binding
affinities of MSH peptides

















5.5. Binding of alanine substituted analogues of a-MSH
Dissociation constants were obtained as described above, and are shown in Table
5.2., together with values relative to a-MSH. Alanine replacements in the terminal 
regions of the peptide (amino acids 1-3 and 10-13) did not significantly change the 
binding affinity of the hormone, except for [Ala2]a-MSH that showed only 14% of 
the binding of a-MSH; this difference was statistically significant at p<0.05. 
Within the peptide core -Met-Glu-His-Phe-Arg-Trp-, substitution of Glu5 was 
possible without a significant loss of affinity, giving a peptide with 87% of the 
binding affinity of the natural compound. Replacement of Met4 and His6 reduced 
the binding to 7% and 17% of that of a-MSH, respectively. Substitution of Phe7 
and Trp9 led to peptides with 100 times lower affinity, and the exchange of Arg8 
gave a compound with 0.0049% of the affinity of a-MSH. [Ala7]a-MSH, [Ala8]a- 
MSH and [Ala9]a-MSH have a binding that is significantly different not only from 
a-MSH, but also from [Ala4]a-MSH and [Ala6]a-MSH (Fig. 5.6.).
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Table 5.2. Dissociation constants (±SD; molar values) of alanine analogues of a -
MSH and binding relative to a-MSH


























































Fig. 5.6. Relative affinities of alanine substituted a-MSH derivatives to the MC3 
receptor. Individual bars represent single experiments.
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Binding of a-MSH, y-MSH and of Related Peptides to the 
MC3 Receptor
The MC3-receptor is a novel melanocortin receptor, whose biological role is as yet 
undiscovered, and although several MSH peptides have been tested for binding and 
stimulation of adenylate cyclase, no attempts have been made to study the 
structure-activity relationships.
A modified method for assaying the receptor binding had to be employed because 
the transfected cells expressing the receptor did not maintain a monolayer for the 
required period of time. Binding experiments carried out in 96-well filtration plates 
are a practical alternative to assays carried out in a monolayer or in suspension. 
The plates facilitate the washing procedure and allow assays to be carried out 
where there are problems with the detachment of cells, i.e. during long incubations 
or under unfavourable conditions. They also facilitate the handling of larger 
numbers of test points at a time. Control experiments with B16 murine melanoma 
cells carried out in 24-well plates and 96-well plates showed that there is no 
significant difference in the dissociation constant between methods. Non-specific 
binding to the plates was high in the absence of cells, but lower in the presence of 
cells. Non-specific binding to empty wells could not be reduced by excess 
unlabelled [Nle4,D-Phe7]a-MSH.
6.1. Time-course of binding
As in B 16 cells, binding at 37°C reached a maximum and then constantly 
decreases. The time that it takes to achieve this maximum binding was significantly 
longer than it took with B16 cells (lh  vs. 0.35h) as described by Eberle (1988) and 
Erskine-Grout (1993). This might be due to the higher number of receptors per cell 
(appr. 50,000 as compared to 10,000-20,000) or the lower affinity of the ligand, or 
both. Also, the ligand, once internalised, might be recycled more slowly and so 
appear within the cells for a longer period of time. To this time, no internalisation 
experiments have been carried out on these cells and they might be of limited value 
as the ligand does not possess a natural function in these cells. The decrease in 
binding after reaching the maximum is likely to be due to degradation of the 
receptor-ligand complex within the cell. Non-specific binding is low and does not 
increase with time. At 0-4°C, binding had reached equilibrium after 24h.
6.2. Binding of [125I-Tyr2,NIe4,D-Phe7]a-MSH
The dissociation constant obtained in replicate experiments was 1.66nM, thus 
[125I-Tyr2,Nle4,D-Phe7]a-MSH has a three times lower affinity to these receptors 
than to B16 a-MSH receptors. As expected, there was only one population of 
receptors present. The number of receptors per cell appeared to decrease with 
passage number, starting with >50,000 receptor per cell for passage 10 decreasing 
to approximately 10,000 receptors per cell with passage 21. This might be caused 
by a small number of cells without the gene encoding the receptor, present in the 
original population, that proliferate at a slightly higher rate than the transfected 
cells. Although a correct estimate of the receptor number is not crucial for the 
calculation of the affinity of the ligand, to avoid errors caused by a only small 
amount of specifically bound radioactivity, only cells with passage numbers 
between 10 and 20 were used in the binding assays.
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6.3. Binding of endogenous MSH peptides and [Nle4,D-Phe7]a-MSH
a-MSH bound with an affinity of 2.07pM to the MC3 receptor, des-acetyl a-MSH 
showed a slightly lower dissociation constant of 0.717|iM. yr MSH showed a 
similar affinity, 3.24jjM. [Nle4,D-Phe7]a-MSH bound 100 times more strongly 
than both natural peptides. This result is in disagreement with findings by Roselli- 
Rehfuss et al. (1993), who found a similar dissociation constant for [Nle4,D- 
Phe7]a-MSH, but significantly higher affinities for a-MSH, yr MSH and y2-MSH. 
Affinities of a-MSH and y2-MSH reported in their study were only approximately 
5 times lower than that of [Nle4,D-Phe7]a-MSH. These studies, however, were 
performed in suspension at 37°C using a significantly lower concentration of [125I- 
Tyr2,Nle4,D-Phe7]a-MSH. There have been no investigations on the influence of 
the temperature on dissociation constants. At 37°C a range of problems might 
arise due to internalisation and/or degradation of the ligand. To avoid this, Roselli- 
Rehfuss et al., employed a variety of protease inhibitors. The presence of 
bacitracin, however, has been reported to significantly reduce specific binding in 
B16 melanoma cells (Siegrist et al., 1988) and it is possible that this might also 
affect the results in other cell lines. Also, a very short incubation time of 10 
minutes was used in this assay, whereas our results indicate that maximum binding 
is only reached after more than lh. Possibly, some variation might have been 
generated by use of different software for data analysis. The possibility of obtaining 
lower values for a-MSH and y^MSH in our study due to more permanent binding 
of the D-Phe7 analogues to the receptor during a 24h incubation has been 
eliminated by carrying out experiments with B16 cells, that showed that the Kj 
estimated from these experiments is similar to those obtained in a 8h incubation 
(see section 3.2.1.) and to those reported in the literature (Eberle, 1988). Also, 
affinity values for a-MSH on melanoma cells obtained with a method similar to the 
one employed by Roselli-Rehfuss et al. were approximately ten times higher than 
reported before in the literature (Tatro et al., 1990).
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Roselli-Rehfuss et al. found that a whole range of MSH peptides, including 
[Nle4,D-Phe7]a-MSH, a-MSH, yr MSH and y2-MSH, stimulated cAMP 
generation with EC50 values very similar to each other. Des-acetyl-a-MSH was the 
least active peptide in the cAMP assay, with an EC50 that was approximately 10 
times lower than that of [Nle4,D-Phe7]a-MSH, the most active peptide. No binding 
data was reported for this compound, but the data reported here suggests that des- 
acetyl-a-MSH binds more strongly than a-MSH or yr MSH. Data from the cAMP 
assay published by Roselli-Rehfuss et al. was generally in agreement with data 
reported for the human equivalent of this receptor, where a-MSH, P-MSH, y- 
MSH, ACTH and [Nle4,D-Phe7]a-MSH triggered an equal biological response as 
measured by a cAMP assay (Gantz et al., 1993a). The biological response of a 
peptide does not necessarily have to correspond to its receptor binding, but further 
studies will be needed to give an answer to this discrepancy between the results 
from the respective cAMP assays and the binding studies reported here.
6.4. Binding of alanine-substituted analogues of a-MSH
Because of the similar affinity of a-MSH and Yj-MSH to this receptor, alanine 
analogues of a-MSH were assayed for receptor binding to investigate which amino 
acids are particularly important for the interaction of the peptide with this receptor. 
In the N-terminal part of the peptide, [Ala^a-MSH and [Ala3]a-MSH did not 
show a significantly different dissociation constant from a-MSH. The normal 
residues in those positions are serine, which can be found in a-MSH and ACTH, 
but not in P-MSH and y-MSH. Exchange of Tyr2 led to reduction of the binding 
affinity to 14% of that of a-MSH. Tyr2 is conserved in all MSH/ACTH sequences, 
and it might possibly have a role in receptor recognition. It has been proposed that 
the tyrosine residue is a requirement for the stimulation of the biological action on 
the MC4 receptor (Gantz et al., 1993b), but no such investigations have been 
made for the MC3 receptor. Any of the C-terminal amino acids can be replaced
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without significant loss of affinity, although the dissociation constant of [Alan ]a- 
MSH is significantly different from those of [Ala12]a-MSH and [Ala13]a-MSH, but 
not from that of a-MSH. Within the core sequence, a -M S H ^ , position 5 is the 
only one which is not conserved in all MSH/ACTH peptides, and also the only one 
which can be replaced by alanine without loss of binding affinity. Substitution of 
Met4 and His6 gave peptides with a similar affinity, their relative affinities being 7% 
and 17%, respectively. It has been observed that, as on the MCI receptor, isosteric 
replacement of Met4 by norleucine is possible without loss of receptor binding. The 
most important residues are clearly contained within the -Phe7-Arg8-Trp9- triplet. 
Replacement of Phe7 or Trp9 lowered the affinity by 100 fold, and substitution of 
Arg8 reduced the affinity by 200 fold.
Alanine analogues can be grouped according to their affinity: analogues with an 
affinity similar to a-MSH: [Ala^a-MSH, [Ala3]a-MSH, [Ala5]a-MSH, [Ala10]a- 
MSH, [Alan ]a-MSH, [Ala12]a-MSH and [Ala13]a-MSH; those with 
approximately 10 times lower affinity: [Ala2]a-MSH, [Ala4]a-MSH and [Ala6]a- 
MSH; and those with 100-200 times lower receptor binding: [Ala7]a-MSH, 
[Ala8]a-MSH and [Ala9]a-MSH. With the exception of [Ala2]a-MSH, all 
replacements that led to reduced binding affinity were made within the so-called 
core sequence, a -M S H ^.
6.5. Summary
The significantly higher affinity of the D-Phe7 analogues [Nle4,D-Phe7]a-MSH and 
[125I-Tyr2,Nle4,D-Phe7]a-MSH indicates that this configuration might lead to 
"irreversible" binding of the peptide to the receptor in a similar way to that 
suggested for the MCI receptor (Eberle, 1988). Iodination of [Nle4,D-Phe7]a- 
MSH increased its affinity 10 fold, so that higher lipophilicity in this region must
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lead to stronger interaction with the receptor. Again, this is very similar to 
observations made on the MCI receptor.
The N-terminal acetyl group does not appear to be required by the receptor, and 
there is a small chance that the desacetyl form is actually the one preferred by the 
receptor, but, although des-acetyl-a-MSH bound with a slightly higher affinity 
than a-MSH itself, the data reported here is not strong enough to support this 
hypothesis.
In this study, there is no indication that this receptor might provide a site of action 
for a specific physiological role for y-MSH as has been proposed in the literature 
(Roselli-Rehfuss et al., 1993). Of course, not all y-MSH peptides have been tested 
for receptor binding and/or biological action on this receptor and as little is known 
about the physiological role of those peptides or their active forms, it is quite 
possible that the peptides known as y-MSHs are not actually the form required by 
the receptor to stimulate biological action. y-MSH peptides bind as strongly as 
other melanotropic peptides to the receptor, and they trigger the biological 
response in the same way.
It has been suggested, that the a-MSH^^-sequence is recognised by the MC3 
receptor because all MSH peptides bind equally well to the receptor (Gantz et al., 
1993a). The results presented here are generally in agreement with that view; but 
in addition it has been shown, that the Glu/Gly in position 5 and the Gly/Asp in 
position 10 are not necessary for the receptor recognition, and that additional 




This chapter will compare the binding affinities of the various peptides studied to 
each other. The two series of peptides used were firstly a group of endogenous 
MSH peptides and the synthetic derivative [Nle4,D-Phe7]a-MSH and secondly the 
alanine-substituted analogues of a-MSH. Results for the individual receptors are 
described in chapters 3 and 4, and chapters 5 and 6, respectively. The amino acid 
sequence of the receptors will be compared, and conserved amino acids likely to 
interact with the ligand will be assigned.
7.1. Comparison of binding to MCI and MC3 receptor
Binding studies could be carried out with both sets of receptors, but biological 
activity was only measured on the MCI receptor, as the 293 cells transfected with 
the gene encoding the MC3 receptor do not possess cellular enzymes for the 
normal melanin biosynthetic pathway.
7.1.1. Endogenous MSH ligands and [Nle4,D-Phe7]a-MSH
Binding of several endogenous MSH ligands had been measured before (compare 
Eberle, 1988; Roselli-Rehfuss et a l , 1993), but there was no binding data available 
for y,-MSH on MCI or for desacetyl-a-MSH on the MC3 receptor. As the MC3 
receptor is regarded as a putative site of action of y-MSH peptides, Yj-MSH as the 
shortest compound out of this group of peptides was chosen for assay. y2-MSH 
has an extra glycine at the C-terminus, and y3-MSH was less active than YrMSH
and y2-MSH in earlier studies (Roselli-Rehfuss et al., 1993). On the MCI receptor, 
Yj-MSH exhibited 0.39% of the affinity of a-MSH, thus binding significantly less 
than both a-MSH and P-MSH. It was also reported to exhibit veiy little or no 
biological activity on the MCI receptor in Cloudman S91 melanoma cells 
(Slominski et al., 1992). In the work reported here, the affinity of YrMSH to the 
MC3 receptor was of the same order of magnitude as that to the MCI, but here a- 
MSH showed approximately the same receptor binding as YrMSH (Table 7.1.). 
Compared to its action on the MCI, it retained only 1% of its affinity. Desacetyl- 
a-MSH was chosen as a test compound on both receptors to investigate the 
influence of the N-terminal acetylation, that is part of the a-MSH molecule, but 
not of YrMSH. It appeared to influence the binding to the MC3 slightly with the 
desacetyl-derivative being approximately 3 times as active as a-MSH itself. 
However, this difference was not significant enough to fully support the 
hypothesis. On the MCI receptor, desacetyl-a-MSH showed the same affinity as 
a-MSH. This is in agreement with values reported by Eberle (1988). [Nle4,D- 
Phe7]a-MSH binds more strongly than a-MSH to both types of receptor, but the 
potentiating factor is 10 for the MCI and 100 for the MC3 receptor. Originally it 
was thought that this could be caused by the longer incubation times used in assays 
involving the MC3 receptor, but control experiments with B16 cells showed no 
significant difference in the dissociation constants obtained with a 8h and a 24h 
incubation period. However, findings by Roselli-Rehfuss et al. (1993) and Gantz et 
al. (1993a) suggest that the biological activity of [Nle4,D-Phe7]a-MSH on the 
MC3 is not much higher than that of a-MSH.
There is a difference in the responsiveness of each receptor to various peptides, 
and they also show a different sensitivity with the dissociation constants for the 
native ligands varying by a factor of 100. The MCI receptor clearly prefers a- 
MSH as a ligand, whereas there is no pharmacological differentiation between a- 
MSH and YrMSH on the MC3 receptor.
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Table 7.1. Comparison of the relative binding affinities of endogenous MSH 





y,-m s h 0.0039 0.0066
7.1.2. Alanine-substituted analogues of a-MSH
As a-MSH was the preferred ligand on the MCI receptor and showed the same 
affinity for the MC3 receptor as Yj-MSH, it seemed a suitable candidate for the 
investigation of the structure-activity relationships on this receptor. All thirteen 
alanine-substituted analogues of the hormone have been tested for receptor 
binding. Binding to both receptors generally followed the same pattern (Fig. 7.1.) 
with the N-terminal amino acids not being so important for the affinity to the 
receptor and the hexapeptide a -M S H ^  forming an essential "core sequence".
Within the peptide core, glutamic acid in position 5 could be replaced by alanine 
without affecting the binding to either receptor and thus indicating that the charged 
side-chain of this residue is not required for the action of the hormone. 
Replacement of Met4 and His6 reduced the affinity to both receptors significantly, 
but the most crucial residues were Phe7-Arg8-Trp9 in both cases. The binding of 
the peptide to the MCI receptor was generally more affected by amino acid 
substitution; this can probably be explained by its higher initial binding affinity.
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In the terminal parts of the peptide, presence of the proline in position 12 was 
favourable to the binding on the MCI receptor, but its absence did not affect the 
binding to the MC3 receptor. Proline in this position is highly conserved within 
melanocortin peptides: it can also be found in P-MSH and ACTH, but not in y{- 
MSH. This might partly explain the very low affinity of these MSH peptides to this 
particular receptor, but the influence of the residue is not strong enough to account 
for this on its own. Another possible way of distinguishing between the two 
peptides might be the aspartic acid residue in position 10 in yj-MSH. Although the 
glycine of a-MSH can be replaced by alanine without affecting the properties of 
the hormone, it can also be replaced by lysine (as in [Nle4,Asp5,D- 
Phe7,Lys10,Arg11]a-MSH; see Chapter 3), and maybe an amino acid with the 
opposite charge cannot be introduced into this position without loss of affinity to 
the MCI receptor.
An extra requirement of the MC3 receptor is the tyrosine in position 2. This 
residue can however be found in all MSH/ACTH peptides, and therefore cannot 
exhibit any selectivity towards one of the peptides. It has been discussed that on 
the MCI the tyrosine in this position might actually participate in non-specific 
interaction with the receptor due to its hydrophobicity (see section 4.2.), a 
hypothesis that is supported by the fact that the affinity of the peptide is increased 
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Fig. 7.1. Relative binding affinities of alanine-substituted a-MSH analogues to the 
MCI and MC3 receptor.
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7.2. Structural similarity of the MCI and MC3 receptor
The seven transmembrane domains of the two receptors were assigned by 
hydrophobicity analysis and sequence homology (Pouton et al., 1994). The amino 
acid sequences of the MCI and MC3 receptor have been fitted to the universal 
template for G protein-coupled receptors developed by Baldwin (1993). Fig. 7.2. 
shows the MC3 receptor fitted to this model. There is a «43% similarity between 
the murine melanoma MCI and the rat hypothalamus MC3 (Roselli-Rehfuss et al., 
1993; see Fig. 7.3.). They share several structural features, including the absence 
of a generally conserved cysteine in the first extracellular loop that is believed to 
form a disulfide bridge with the second extracellular loop in most G-protein 
coupled receptors. Also, their second extracellular loop is very short, or almost 
non-existent. These characteristics can also be found in the MC2 receptor (ACTH 
receptor; Mountjoy et al., 1992). No similarities can be observed in the N-terminal 
region or in the extracellular parts of the receptor. There are significantly more 
similar features within the transmembrane regions, and the first and second 
intracellular loop are highly conserved. This is not surprising as these loops are 
generally very similar in all G protein-coupled receptors, and are thought to be 
important for the interaction with the G protein. The Asp148-Arg149-Tyr150 
(numbering with reference to the MC3 receptor) motif on the intracellular side of 
helix III is thought to be crucial for G protein binding (Hargrave, 1991) and is 
highly conserved in all G protein-coupled receptors.
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Fig. 7.2. Amino acid sequence of the MC3 receptor fitted to the Baldwin template 
(Baldwin, 1993)
D ® ® -N H 2
COO 11
i l l





7.3. Proposed mechanism for interaction of MSH peptides 
with the receptors
The tetrapeptide His6-Phe7-Arg8-Trp9 is common to all melanotropic peptides and 
has been shown to play a major role in receptor binding and stimulation of 
biological activity of a-MSH. The development of a putative tertiary structure of 
the MSH receptor by Pouton et al. (1994) allows a hypothesis of the nature of the 
interaction of this tetrapeptide with the receptors. His6-Phe7-Arg8-Trp9- might bind 
to a small number of conserved residues that are located near the extracellular 
surfaces of the helices. These residues have been proposed to be Phe45, Glu94, one 
of Asp117 or Asp121 and Phe282 (numbering in reference to the MC3 receptor; see 
Fig. 7.4.) as there are few conserved residues that are able to interact with the 
ligand. This is equivalent to the amino acids in position 43, 92, 115, 119 and 277, 
respectively, in the MCI receptor. The importance of the glutamate residue is 
known from a naturally occurring mutation on the MCI receptor: a murine mutant, 
the so-called sombre mutant, shows a lysine in this position, and this receptor is 
constituitively active in cells cultured in the absence of the hormone (Robbins et 
al., 1993). It was therefore suggested that the receptor might form a salt bridge 
with one of the aspartic acid residues within the third helix when bound to the 
ligand. The mutant receptor can form the bridge without the presence of MSH. 
The formation of the bridge might then result in a spatial rearrangement of the 
helices II and III, and thus trigger the response of the G protein (Pouton et al., 
1994).
No propositions have been made concerning the interaction of methionine, which 
has proven essential for the binding to both receptors, with the receptor. The 
mechanism of the recognition of either proline (on the MCI) or tyrosine (on the 
MC3) remains unsolved.
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Fig. 7.4. Proposed amino acids for interaction with the His^-Phe^-Arg^-Trp^ part 





The organisation of the information within the a-MSH molecule has been 
investigated in the work presented in this thesis. What needs to be understood next 
is the exact molecular interaction of the molecule with the receptor. If the 
proposals made concerning the binding site for the common tetrapeptide His6- 
Phe7-Arg8-Trp9 are correct, the influence of the other residues that are important 
for binding or activity can then be localised. The reason for the low binding affinity 
of y-MSH peptides on the MCI should be further investigated; the proline in 
position 12 of the a-MSH molecule and in the corresponding positions in p-MSH 
and ACTH needs to be looked at in detail. Also, the importance of the tyrosine for 
the binding to the MC3 is very interesting and could be further studied by 
replacement by amino acids other than alanine, or by peptidomimetics. To study 
the molecular interaction of the hormone with the ligand, point mutation 
experiments can be carried out with the receptor, changing one by one those 
residues of the receptor that are thought of importance for the binding of certain 
residues within the ligand molecule. Corresponding synthetic peptides can be 
designed that match the mutation site, and could be tested for binding and 
biological activity on both receptors. The question why some of the a-MSH 
analogues exhibit an affinity to the MCI receptor that is significantly different from 
the native hormone, but nearly maintain the full biological activity remains open.
The design of conformationally constrained (i.e. cyclic) analogues with high 
potency remains desirable, so that conformational studies, binding and biological 
activity studies, and hopefully molecular modelling can be carried out 
simultaneously to gain information about the bioactive conformation present at the 
receptor.
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The structure-activity studies for a-MSH on the MCI receptor are in broad 
agreement with the findings in reptilian and amphibian bioassays. The central 
hexapeptide a-M S H ^^  can be looked at as the core sequence of the peptide, 
however, its affinity to the murine melanoma receptor is significantly lower than 
that of the native hormone, and if short sequences were to be employed in drug 
targeting for synthetic convenience, one would have to take the loss of affinity and 
activity into account. Replacement of the Met4 of Nle4 with a drug molecule as 
recently suggested (Morandini et al., 1994) is not advisable as this residue appears 
to be crucial for receptor binding. Binding to receptors within the CNS shows 
almost the same requirements than that to the peripheral MSH receptor in 
melanoma cells. Selectivity towards the latter could therefore at present not be 
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APPENDIX 1
Statistical analysis of the biological data
131
1
MTB > print cl-c4;
SUBC> format(f2,3 (f8.4)).
1 0.1970 0.0019 0.0688
1 0.2110 0.0016 0.0210
1 0.1980 0.0240 0.0253
1 * * 0.0129
2 2.0300 0.1390 0.1390
2 1.5500 0.0220 0.2090
2 2.6100 0.0110 0.1750
2 * 0.1500 *
3 6.3800 0.0470 0.6770
3 4.1400 0.0670 0.2020
3 1.0500 0.2300 0.2950
4 2.7400 0.0073 0.6600
4 13.7000 0.7900 0.8930
4 8.0600 0.7000 1.9100
4 69.9000 * *
4 12.5000 * *
5 5.3800 0.0750 0.0314
5 1.6300 0.0510 0.1480




7 2.9100 0.1020 ★
7 2.0300 0.3300 9.9000
7 2.3300 0.3000 8.5500
7 * * 1.6600
8 47.0000 1.5000 15.0000
8 40.3000 0.2900 52.0000








ANALYSIS OF VARIANCE ON logbind
SOURCE DF SS MS
group 8 155.849 19.481
ERROR 19 8.813 0.464
TOTAL 27 164.662
LEVEL N MEAN STDEV
1 3 -1.6000 0.0383
2 3 0.7019 0.2606
3 3 1.1076 0.9421
4 5 2.4970 1.1687
5 3 1.2295 0.6470
6 2 7.4385 0.4578
7 3 0.8740 0.1817
8 3 3.7917 0.0833
9 3 5.4247 0.3933
POOLED STDEV = 0.6811
F p
42.00 0.000
INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV





( — * — )
(-_*_)
( — * — )
0.0 3.0 6.0
TUKEY'S multiple comparison procedure
Nominal level = 0.0500 
Family error rate = 0.0500 
Individual error rate = 0.00250
Critical value = 4.92
Intervals for (mean of column group) - (mean of row group)
1 2 3 4 5 6


































































FISHER'S multiple comparison procedure
Nominal level ** 0.0500 
Family error rate = 0.505 
Individual error rate * 0.0500
Critical value *= 2.093
Intervals for (mean of column group) - (mean of row group)









































































MTB > let c6 - log(c3)
MTB > name c6 'logtyr'
MTB > onew 'logtyr' 'group'
ANALYSIS OF VARIANCE ON logtyr
SOURCE DF SS MS F p
group 8 179.96 22.49 13.78 0.000
ERROR 18 29.38 1.63
TOTAL 26 209.34
INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
LEVEL N MEAN STDEV
1 3 -5.478 1.516
2 4 -3.049 1.318
3 3 -2.410 0.834
4 3 -1.837 2.670
5 3 -2.719 0.223
6 3 4.009 0.428
7 3 -1.532 0.652
8 3 -0.064 1.024




MTB > onew 'logtyr' 'group'; 
SUBC> fisher;
SUBC> tukey.
ANALYSIS OF VARIANCE ON logtyr
SOURCE DF SS MS
group 8 179.96 22.49
ERROR 18 29.38 1.63
TOTAL 26 209.34
LEVEL N MEAN STDEV
1 3 -5.478 1.516
2 4 -3.049 1.318
3 3 -2.410 0.834
4 3 -1.837 2.670
5 3 -2.719 0.223
6 3 4.009 0.428
7 3 -1.532 0.652
8 3 -0.064 1.024
9 2 1.535 0.715




 + -------------------------+ -
.* )
( — * — ,
( — * — )
( — * — )
( — * — )
( *— )
(------*-








INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV_+ +-------------- +------------ +-
( * )
( * )
( * )( * )
( * )
( *(-----*----- )
(-* )( * )
 +-------------- +------------ +--+ 
-7.0 -3.5 0 . 0 3.5
TUKEY'S multiple comparison procedure
Nominal level * 0.0500 
Family error rate = 0.0500 
Individual error rate = 0.00254
Critical value = 4.95
Intervals for (mean of column group) - (mean of row group)









































































FISHER'S multiple comparison procedure
Nominal level = 0.0500 
Family error rate = 0.502 
Individual error rate = 0.0500
Critical value = 2.101
Intervals for (mean of column group) - (mean of row group)









































































MTB > let c7 = log(c4)
MTB > name c7 'logmel'
MTB > onew 'logmel' 'group'; 
SUBC> fisher;
SUBC> tukey.
ANALYSIS OF VARIANCE ON logmel
SOURCE DF SS MS
group 8 244.062 30.508
ERROR 19 9.891 0.521
TOTAL 27 253.954
LEVEL N MEAN STDEV
1 4 -3.6418 0.7034
2 3 -1.7606 0.2045
3 3 -1.0701 0.6186
4 3 0.0395 0.5475
5 3 -2.4973 0.8411
6 3 5.3880 0.7853
7 3 1.6484 0.9914
8 3 3.0848 0.7524
9 3 3.6516 0.7785
POOLED STDEV = 0.7215
F p
58.60 0.000
INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
(--*-)
(—* " )
( - * " )
(--*—)
(— * — )
(— * — )
(-* — )
(--*“ )( - * - - )
-3.0 0.0 3.0 6.0
1
TUKEY'S multiple comparison procedure
Nominal level = 0.0500 
Family error rate = 0.0500 
Individual error rate « 0.00250
Critical value = 4.92
Intervals for (mean of column group) - (mean of row group)









































































FISHER'S multiple comparison procedure
Nominal level = 0.0500 
Family error rate = 0.505 
Individual error rate = 0.0500
Critical value = 2.093
Intervals for (mean of column group) - (mean of row group)











































































*** Minitab Release 7.2 *** Minitab, Inc. *** 
Storage available 100000 
MTB > stop
*** Minitab Release 9.1 *** Minitab Inc. *** 
Worksheet size: 8000 cells
MTB > print cl c2 c3 c4 c5 c6 c7
ROW Cl C2 C3 C4 logbind logtyr logmel
1 1 1.7 0.0375 0.00585 0.5306 -3.28341 -5.14131
2 1 7.0 0.0110 0.03010 1.9416 -4.50986 -3.50323
3 1 6.6 0.0931 0.03020 1.8856 -2.37408 -3.49991
4 2 6.1 0.0715 0.02530 1.8017 -2.63806 -3.67695
5 2 4.7 0.0856 0.11200 1.5390 -2.45807 -2.18926
6 2 4.7 0.0107 0.18300 1.5476 -4.53751 -1.69827
7 3 2.5 0.0565 0.01500 0.8961 -2.87351 -4.19971
8 3 1.5 0.0006 0.04080 0.4253 -7.35248 -3.19907
9 3 1.2 0.0183 , 0.02680 0.1740 -4.00085 -3.61935
10 3 * 0.0449 * * -3.10332 *
11 4 408.0 1.0300 3.15000 6.0113 0.02956 1.14740
12 4 139.0 4.6200 0.40700 4.9345 1.53039 -0.89894
13 4 302.0 5.4200 0.70900 5.7104 1.69010 -0.34390
14 5 1.1 0.0297 * 0.1310 -3.51661 *
15 5 1.2 0.0373 * 0.1906 -3.28876 *
16 5 0.5 0.1470 * -0.7853 -1.91732 ★
17 5 0.4 0.1340 * -0.7985 -2.00992 *
18 5 0.3 0.4020 ★ -1.0729 -0.91130 *
19 6 308.0 0.4550 1.40000 5.7301 -0.78746 0.33647
20 6 95.5 0.2100 0.06660 4.5591 -1.56065 -2.70905
21 6 106.0 0.8950 0.97900 4.6634 -0.11093 -0.02122
22 7 1220.0 7.1100 3.77000 7.1066 1.96150 1.32708
23 7 664.0 6.8000 1.90000 6.4983 1.91692 0.64185
24 7 1020.0 28.9000 2.31000 6.9276 3.36384 0.83725
25 7 1300.0 20.6000 * 7.1701 3.02529 *
26 8 306.0 10.7000 * 5.7236 2.37024 ★
27 8 77800.0 4.2900 * 11.2619 1.45629 ★
28 8 2290.0 22.2000 * 7.7363 3.10009 *
29 8 3840.0 8.9100 ★ 8.2532 2.18717 ic
30 9 691.0 3.0600 * 6.5381 1.11841 ic
31 9 5790.0 10.7000 * 8.6639 2.37024 ic
32 9 5.9 0.0688 * 1.7716 -2.67655 ic
33 10 1.9 0.0163 * 0.6152 -4.11659 ic
34 10 29.9 0.0373 * 3.3979 -3.28876 ic
35 10 1.1 * * 0.1133 * ★
36 10 0.7 0.8190 ★ -0.3467 -0.19967 ★
37 11 4.6 0.0722 4c 1.5239 -2.62832 *
38 11 2.1 0.0114 * 0.7467 -4.47414 *
39 11 4.1 0.0389 * 1.4159 -3.24676 *
40 11 * 0.5460 4r ★ -0.60514 *
41 12 20.7 0.3910 4c 3.0301 -0.93905 ★
42 12 14.6 0.0978 4r 2.6810 -2.32483 *
43 12 28.8 0.0065 * 3.3604 -5.03135 ★
44 13 1.8 0.0007 4c 0.5596 -7.33700 ★
45 13 1.2 0.0579 4c 0.1655 -2.84904 ★
46 13 2.5 0.0102 4c 0.9163 -4.58537 *
47 13 * 0.0159 4c 4c -4.14144 ★
48 13 ★ 0.1550 4r 4c -1.86433 ★
49 14 2.0 0.0220 0.13900 0.7080 -3.81671 -1.97328
50 14 1.5 0.0110 0.20900 0.4383 -4.50986 -1.56542
51 14 2.6 0.1500 0.17500 0.9594 -1.89712 -1.74297
52 14 * * 0.26300 4c ★ -1.33560
53 14 * * 0.25900 * * -1.35093
MTB > onew 'logbind' cl;
SUBC> fisher




























INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV 
 + + + +-
1 3 1.453 0.799 (---*— -)
2 3 1.629 0.149 (----*- — )
3 3 0.498 0.367 (-- *----)
4 3 5.552 0.556 (-- *---)
5 5 -0.467 0.585 (-- *")
6 3 4.984 0.648 (-— *--- )
7 4 6.926 0.303 (-- *---)
8 4 8.244 2.289 (---*
9 3 5.658 3.529 (-- *---)
10 4 0.945 1.682 (---*— )
11 3 1.229 0.421 (----*— -)
12 3 3.024 0.340 (— -)
13 3 0.547 0.376 (----*---)
14 3 0.702 0.261 (---*---)
iED STDEV = 1.289 0.0 3.5 7.0
1
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.000993
Critical value - 5.11
Intervals for (column level mean) - (row level mean)













































































































































































Family error rate *■ 0.305 
Individual error rate = 0.0100
Critical value = 2.733
Intervals for (column level mean) - (row level mean)




































































































































































































ANALYSIS OF VARIANCE ON logtyr
SOURCE DF SS MS
C l 13 267.16 20.55
ERROR 36 87.93 2.44
TOTAL 49 355.09
LEVEL N MEAN STDEV
1 3 -3.389 1.072
2 3 -3.211 1.152
3 4 -4.333 2.071
4 3 1.083 0.916
5 5 -2.329 1.074
6 3 -0.820 0.725
7 4 2.567 0.738
8 4 2.278 0.675
9 3 0.271 2.628
10 3 -2.535 2.064
11 4 -2.739 1.616
12 3 -2.765 2.081
13 5 -4.155 2.077
14 3 -3.408 1.353




INDIVIDUAL 95 PCT Cl'S FOR MEAN 





( * )(------ * )
( * )( * )
( * )
( * )





Family error rate = 0.0500 
Individual error rate = 0.000975
Critical value = 5.08
Intervals for (column level mean) - (row level mean)

























































































































































































Family error rate = 0.309 
Individual error rate = 0.0100
Critical value = 2.719







-4.164 -3.986 -4.854 0.309
2.043 2.221 0.847 6.515
-6.039 -5.861 -6.758 -1.567 -4.612
0.900 1.078 -0.267 5.373 1.594
-9.202 -9.024 -9.904 -4.729 -7.746 -6.632

































































































































































ANALYSIS OF VARIANCE ON logmel
SOURCE DF SS MS F p
C l 6 61.900 10.317 12.95 0.000
ERROR 16 12.745 0.797
TOTAL 22 74.645
INDIVIDUAL 95 PCT C l 'S  FOR MEAN
BASED ON POOLED STDEV
LEVEL N MEAN STDEV 1 I I 1 1 I + 1 I I I I 1 1 1 I + 1 I I 1 I I I I 1 + I 1 1 1 I I I 1 I +
1 3 -4.0482 0.9467 (-----*----)
2 3 -2.5215 1.0303 (----*-----)
3 3 -3.6727 0.5024 (-----*----)
4 3 -0.0318 1.0583 (-----*----)
6 3 -0.7979 1.6647 (----*----)
7 3 0.9354 0.3530 (-----*----)
14 5 -1.5936 0.2705 (-- *---)









Tukey' s pairwise comparisons
Family error rate * 0.0500 
Individual error rate = 0.00405
Critical value *= 4.74
Intervals for (column level mean) - (row level mean)













































rate * 0.110 
rate « 0.0100
Critical value = 2.921
Intervalsi for (column level mean) - (row level mean)













































MTB > onew 'logbind' cl;
SUBC> fisher.
ANALYSIS OF VARIANCE ON logbind 
SOURCE DF SS MS
Cl 13 375.87 28.91
ERROR 33 54.81 1.66
TOTAL 46 430.68
LEVEL N MEAN STDEV
1 3 1.453 0.799
2 3 1.629 0.149
3 3 0.498 0.367
4 3 5.552 0.556
5 5 -0.467 0.585
6 3 4.984 0.648




INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
( * )





8 4 8.244 2.289 (---*— )
9 3 5.658 3.529 (-- *---)
10 4 0.945 1.682 (---*— )
11 3 1.229 0.421 (----*---)
12 3 3.024 0.340 (----*---)
13 3 0.547 0.376 (----*---)
14 3 0.702 0.261 (---*---)
POOLED STDEV = 1.289 0.0 3.5 7.0 10
Fisher' s pairwise comparisons
Family error rate = 0.736 
Individual error rate ■ 0.0500
Critical value ** 2.035
Intervals for (column level mean) - (row level mean)



































































































































































13 5.694 2.969 -1.605 -1.460















MTB > onew 'logtyr' cl;
SUBC> fisher.
ANALYSIS OF VARIANCE ON logtyr
SOURCE DF SS MS
C l 13 267.16 20.55
ERROR 36 87.93 2.44
TOTAL 49 355.09
LEVEL N MEAN STDEV
1 3 -3.389 1.072
2 3 -3.211 1.152
3 4 -4.333 2.071
4 3 1.083 0.916
5 5 -2.329 1.074
6 3 -0.820 0.725
7 4 2.567 0.738
8 4 2.278 0.675
9 3 0.271 2.628
10 3 -2.535 2.064
11 4 -2.739 1.616
12 3 -2.765 2.081
13 5 -4.155 2.077
14 3 -3.408 1.353
POOLED STDEV - 1.563
F i s h e r ' s  p a i r w i s e ! c o m p a r is o n s
F a m ily  e r r o r r a t e  = 0.741




INDIVIDUAL 95 PCT Cl'S FOR MEAN 




( * ) 
( * )(------ * )







-3.0 0 . 0 3.0
Critical value = 2.028
Intervals for (column level mean) - (row level mean)

























































































































































































MTB > onew 'logmel' cl;
SUBC> fisher.
ANALYSIS OF VARIANCE ON logmel
SOURCE DF SS MS F p
C l 6 61.900 10.317 12.95 0.000
ERROR 16 12.745 0.797
TOTAL 22 74.645
INDIVIDUAL 95 PCT C l 'S  FOR MEAN
BASED ON POOLED STDEV
LEVEL N MEAN STDEV +1I111111I+1i11111I1+II1111I11+I1I1II
1 3 -4.0482 0.9467 (---------*------- )
2 3 -2.5215 1.0303 (-------*--------- )
3 3 -3.6727 0.5024 (---------*------- )
4 3 -0.0318 1.0583 (---------*------- )
6 3 -0.7979 1.6647 (-------*------- )
7 3 0.9354 0.3530 (---------* ------- )
14 5 -1.5936 0.2705 (-----*----- )
POOLED STDEV = 0.8925 -4.0 -2.0 0.0 2.0
Fisher's pairwise comparisons
Family error rate = 0.387 
Individual error rate = 0.0500
Critical value = 2.120
Intervals for (column level mean) - (row level mean)





































MTB > onew c5 cl; 
SUBC> fisher 0.01; 
SUBC> tukey.





































INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV 
 +--------- +-------- +-




- 1 . 0  0 . 0  1 . 0
Tukey's pairwise comparisons
Family error rate *= 0.0500 
Individual error rate = 0.0122
Critical value = 4.42














Family error rate = 0.0412 
Individual error rate = 0.0100
Critical value = 3.251













MTB > onew c5 cl; 
SUBC> fisher.

























INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
( - - * " )
2 4 -1.1823 0.3739 (— *— )
3 3 -1.3040 0.1151 (--*— )
4 3 0.7019 0.2606 (— *--)
 I —----  +------------—I—
POOLED STDEV = 0.2546 -1.0 0.0 1.0
1
F i s h e r ' s  p a i r w i s e  c o m p a r is o n s
F a m ily  e r r o r  r a t e  = 0.178 
I n d i v i d u a l  e r r o r  r a t e  = 0.0500
C r i t i c a l  v a l u e  *= 2.262













MTB > onew  c6  c l ;  
SUBC> f i s h e r  0.01; 
SUBC> t u k e y .





































INDIVIDUAL 95 PCT C l 'S  FOR MEAN 
BASED ON POOLED STDEV
( * )
( * )
( * )( * )
-8.0 -6.0 -4.0 -2.0
1
T u k e y 's  p a i r w i s e  c o m p a r is o n s
F a m ily  e r r o r  r a t e  = 0.0500 
I n d i v i d u a l  e r r o r  r a t e  = 0.0122
C r i t i c a l  v a l u e  = 4.42







F i s h e r ' s  p a i r w i s e  c o m p a r is o n s
F a m ily  e r r o r  r a t e  = 0.0412 
I n d i v i d u a l  e r r o r  r a t e  = 0.0100
Critical value = 3.251
Intervals for (column level mean) - (row level mean) 













MTB > onew c6 cl;
SUBC> fisher.





































INDIVIDUAL 95 PCT Cl'S FOR MEAN 





 +----------+--------- +-------- +-
-8.0 -6.0 -4.0 -2.0
Fisher's pairwise comparisons
Family error rate = 0.178 
Individual error rate = 0.0500
Critical value = 2.262













MTB > onew c7 cl; 
SUBC> fisher 0.01; 
SUBC> tukey.


































INDIVIDUAL 95 PCT Cl'S FOR MEAN 






Family error rate = 0.0500 
Individual error rate = 0.0206
Critical value = 3.82








Family error rate = 0.0249 
Individual error rate = 0.0100
Critical value = 3.109






MTB > onew c7 cl;
SUBC> fisher.
ANALYSIS OF VARIANCE ON C7
SOURCE DF SS MS
C l 2 29.37 14.68
ERROR 11 17.70 1.61
TOTAL 13 47.07
LEVEL N MEAN STDEV
1 6 -4.615 1.617
2 3 -4.619 1.471
4 5 -1.594 0.271
POOLED STDEV = 1.269
Fisher's pairwise comparisons
Family error rate = 0.115 
Individual error rate = 0.0500
Critical value = 2.201








INDIVIDUAL 95 PCT Cl'S FOR MEAN 












MTB > onew c5 cl; 
SUBC> fisher 0.01; 
SUBC> tukey.




































INDIVIDUAL 95 PCT C l 'S  FOR MEAN 
BASED ON POOLED STDEV
 +------------ +---------------+-----------
( - * - - )
( - * - - )
 +------------ +---------------+-----------
0.0 1.5 3.0 4
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate * 0.0126
Critical value = 4.53














Family error rate = 0.0403 
Individual error rate *= 0.0100
Critical value = 3.356













MTB > onew c5 cl;
SUBC> fisher.

























INDIVIDUAL 95 PCT C l ' S  FOR MEAN 
BASED ON POOLED STDEV
( _ _ * — )
2 3 2.1142 0.1116 (— *— )
3 3 -0.4359 0.2898 (--*— )
4 3 0.7019 0.2606 (--*— )-------—— i— ----————i-
POOLED STDEV * 0.3471 0.0 1.5 3.0 4.5
1
Fisher's pairwise comparisons
Family error rate = 0.176 
Individual error rate = 0.0500-
Critical value = 2.306














MTB > onew c6 cl; 
SUBC> fisherO.01; 
SUBC> tukey.



































POOLED STDEV = 0.8730
INDIVIDUAL 95 PCT Cl'S FOR MEAN 





-6.0 -4.5 -3.0 -1.
1
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.0126
Critical value = 4.53














Family error rate = 0.0403 
Individual error rate = 0.0100
+ 
m
Critical value = 3.356





4 -1.4233 -1.4834 -4.2783
3.3612 3.3011 0.5062
MTB >
MTB > onew c6 cl;
SUBC> fisher.































POOLED STDEV = 0.8730
Fisher's pairwise comparisons
Family error rate ** 0.17 6 
Individual error rate = 0.0500





INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
( * )
( * )( * )
( * )
-6.0 -4.5 -3.0 -1.5
Intervals for (column level mean) - (row level mean)
-1.5837
1.7039










MTB > onew c7 cl;
SUBC> fisher 0.01;
SUBC> tukey.
































INDIVIDUAL 95 PCT Cl'S FOR MEAN 




-+------------- +-------------- +------------- +-----
POOLED STDEV - 0.8354 -2.40 -1.60 -0.80 0.00
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.0209
Critical value * 3.95








Family error rate = 0.0245 
Individual error rate = 0.0100
Critical value = 3.251







MTB > onew c7 cl; 
SUBC> fisher.
ANALYSIS OF VARIANCE ON C7
SOURCE DF SS MS
C l 2 1.268 0.634
ERROR 9 6.281 0.698
TOTAL 11 7.549
LEVEL N MEAN STDEV
1 3 -0.7837 0.8747
2 4 1.1711 1.2191
4 5 -1.5936 0.2705
POOLED STDEV = 0.8354
Fisher's pairwise comparisons
Family error rate = 0.113
Individual error rate = 0.0500
Critical value = 2.262






INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
( * )




MTB > let c3=log(cl)
MTB > let c4=log(c2)
MTB > print cl c2 c3 c4
ROW Cl C2 C3 C4
1 1 137.0 0.00000 4.9200
2 1 219.0 0.00000 5.3891
3 1 567.0 0.00000 6.3404
4 2 1400.0 0.69315 7.2442
5 2 138.0 0.69315 4.9273
6 2 2970.0 0.69315 7.9963
7 3 173.0 1.09861 5.1533
8 3 34.2 1.09861 3.5322
9 3 817.0 1.09861 6.7056
10 4 118.0 1.38629 4.7707
11 4 5590.0 1.38629 8.6287
12 4 3240.0 1.38629 8.0833
13 4 4400.0 1.38629 8.3894
14 4 1450.0 1.38629 7.2793
15 5 110.0 1.60944 4.7005
16 5 213.0 1.60944 5.3613
17 5 18.5 1.60944 2.9178
18 5 145.0 1.60944 4.9767
19 6 225.0 1.79176 5.4161
20 6 107.0 1.79176 4.6728
21 6 246.0 1.79176 5.5053
22 7 19000.0 1.94591 9.8522
23 7 27000.0 1.94591 10.2036
24 7 12300.0 1.94591 9.4174
25 8 39000.0 2.07944 10.5713
26 8 69800.0 2.07944 11.1534
27 8 17600.0 2.07944 9.7757
28 9 20800.0 2.19722 9.9427
29 9 7620.0 2.19722 8.9385
30 9 23000.0 2.19722 10.0432
31 10 179.0 2.30259 5.1874
32 10 402.0 2.30259 5.9965
33 10 218.0 2.30259 5.3845
34 10 290.0 2.30259 5.6699
35 11 417.0 2.39790 6.0331
36 11 600.0 2.39790 6.3969
37 11 1230.0 2.39790 7.1148
38 12 93.7 2.48491 4.5401
39 12 62.2 2.48491 4.1304
40 12 61.5 2.48491 4.1190
41 13 118.0 2.56495 4.7707
42 13 279.0 2.56495 5.6312
43 13 72.9 2.56495 4.2891
44 14 288.0 2.63906 5.6630
45 14 321.0 2.63906 5.7714
46 14 148.0 2.63906 4.9972
47 14 70.5 2.63906 4.2556
MTB > onew c4 cl; 
SUBC> fisher 0.01; 
SUBC> tukey.
ANALYSIS OF VARIANCE ON C4
SOURCE DF SS MS F p
Cl 13 177.991 13.692 14.81 0.000
ERROR 33 30.512 0.925
TOTAL 46 208.503
INDIVIDUAL 95 PCT Cl'S 
BASED ON POOLED STDEV
LEVEL N MEAN STDEV 1II+1I11I1I1I
+111II111
1 3 5.550 0.724 (---*----)
2 3 6.723 1.600 (----*---)
3 3 5.130 1.587 (----*---)
4 5 7.430 1.572 (-- *— )
5 4 4.489 1.082 (---*---)
6 3 5.198 0.457 (----*---)
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rate = 0.0500 
rate - 0.000993
Critical value = 5.11
Intervals for (column level mean) - (row level mean)
























































































































































































rate = 0.305 
rate = 0.0100
Critical value = 2.733
Intervals for (column level mean) - (row level mean)




























































































































































































MTB > onew c4 cl;
SUBC> fisher.
ANALYSIS OF VARIANCE ON C4
SOURCE DF SS MS
C l 13 177.991 13.692
ERROR 33 30.512 0.925
TOTAL 46 208.503
LEVEL N MEAN STDEV
1 3 5.550 0.724
2 3 6.723 1.600
3 3 5.130 1.587
4 5 7.430 1.572
5 4 4.489 1.082
6 3 5.198 0.457
7 3 9.824 0.394
8 3 10.500 0.692
9 3 9.641 0.611
10 4 5.560 0.352
11 3 6.515 0.550
12 3 4.263 0.240
13 3 4.897 0.680
14 4 5.172 0.700




INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV  + + +---
(  *  )
( *  )(----- *-----)
( * _ _ )




( * )( *.
■ *  ) * ,
(  *  )
 +-----------
5.0
■— + -  
7.5
 +.
1 0 . 0
Fisher's pairwise comparisons
Family error rate = 0.736 
Individual error rate ■» 0.0500
Critical value = 2.035
Intervals for (column level mean) - (row level mean)







































































10 -1.5043 -0.3315 -1.9237 0.5581 -2.4541 -1.8560 2.7703

























































8 9 10 11 12 13
9 -0.7391
2.4563
10 3.4461
6.4351
2.5874
5.5765
11 2.3875
5.5829
1.5289
4.7243
-2.4499
0.5391
12 4.6393
7.8347
3.7806
6.9760
-0.1981
2.7909
0.6541
3.8495
13 4.0054
7.2008
3.1468
6.3422
-0.8320
2.1571
0.0202
3.2156
-2.2315
0.9639
14 3.8338
6.8228
2.9752
5.9642
-0.9959
1.7714
-0.1514
2.8376
-2.4032
0.5859
-1.7693
1.2197
